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To investigate predictors of pathological response to radiotherapy for rectal cancer by 
reviewing the evidence, exploring clinicopathological predictors in a local cohort and 
investigating markers of oxidative stress as novel biomarker predictors. 
Method 
A systematic review of the literature was undertaken. A retrospective study of patients 
treated with neoadjuvant chemoradiotherapy (nCRT) and total mesorectal excision at 
Christchurch Hospital 2013-2018 was performed by reviewing patients clinical records. A 
literature review of the role of antioxidants including peroxiredoxins on the effect of ionising 
radiation was performed. A prospective observational pilot study was then performed 
investigating markers of oxidative stress including peroxiredoxin oxidation status and protein 
carbonyls as novel predictors of the response to radiotherapy for rectal cancer. 
Results  
Based on currently available evidence the predictors of pathological response to nCRT for 
rectal cancer with the most clinical utility currently are clinical T and N stage, tumour size 
and CEA level.  In a cohort of 164 patients treated with nCRT and total mesorectal excision 
there was a pathological complete response (pCR) rate of 14.6%; shorter tumour length on 
MRI and lower clinical N stage were independent predictors of pCR on logistic regression. 
Higher BMI, anterior or circumferential tumours and lower haemoglobin were independent 
predictors of minimal-poor response as determined by tumour regression grade. 
The markers of oxidative stress peroxiredoxin 2 and peroxiredoxin 3 percentage oxidation 
and protein carbonyl levels did not predict response to radiotherapy for rectal cancer in 
seven patients treated with nCRT, of which two patients experienced a pCR and one patient 
experienced a complete clinical response. 
Conclusion 
The pathological response to radiotherapy for rectal cancer is complex and numerous factors 
appear to play a role. Predictors can be classified as clinicopathological, biomarker or 
v 
 
radiological predictors. Although there are several clinical predictors of use currently, none 
have a high predictive ability. Neither peroxiredoxin oxidation status or protein carbonyls 
appear to predict the response to radiotherapy for rectal cancer. A composite scoring 
system comprised of clinicopathological, biomarker and radiological factors is most likely to 
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1 Introduction and Systematic Review 
1.1 Introduction 
Colorectal cancer (CRC) is the third most common cancer in the Western world and the 
second most common cancer in New Zealand, where approximately 3000 new cases are 
diagnosed and 1200 deaths occur annually from the disease (1). Approximately one-third of 
cases of CRC are rectal in origin. Colon cancer is generally treated by surgical resection +/- 
adjuvant chemotherapy, usually indicated for lymph node metastases or occasionally for 
advanced T stage tumours. Rectal cancer holds specific treatment challenges compared with 
colon cancer, often requiring specialist surgical care and multi-disciplinary treatment. 
Bowel cancer screening programs reduce death rates from CRC (2), and the introduction of 
screening is currently taking place in New Zealand. This means a larger proportion of 
patients are likely to be diagnosed with curable disease due to earlier diagnosis. There is also 
evidence of a rising incidence of CRC in people under 50 years of age, especially rectal cancer 
in males under 50 years (3). These two factors, combined with advances in treatment, mean 
a greater proportion of long-term survivors may live with the morbidity of rectal cancer 
treatment for decades.  This has major implications for the selection of treatment strategies.  
1.1.1 Modern Management of Rectal Cancer 
Traditionally surgery has been seen as the only curative option for rectal cancer but it carries 
significant risks including a 1-2% in-hospital mortality rate, 31% major complication (Clavien-
Dindo grade 3-4) rate and an approximately 25% chance of a permanent stoma (4), as well as 
the risk of significant post-operative bowel dysfunction known as low anterior resection 
syndrome (LARS) (5). 
Historically, local recurrence in the pelvis was a major problem in the management of rectal 
cancer and local recurrence rates of 25% could be expected (6). Pre-operative radiotherapy 
and TME have significantly reduced this risk (7, 8) and are now standard of care for many 
patients. The standard curative treatment options for localised rectal cancer are surgical 
resection alone or surgical resection after pre-operative (neoadjuvant) or post-operative 
radiotherapy. An alternative strategy of non-operative management (known as ‘watch-and-
wait’ management) is starting to emerge as a viable alternative in appropriately selected 
patients (9). Adjuvant chemotherapy is usually indicated for lymph node metastases and can 
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be considered after resection irrespective of neoadjuvant therapy received. Chemotherapy 
has been shown to improve survival by delaying or preventing systemic recurrence (10). 
The management of patients with distant metastases is usually palliative, although curative 
treatment remains a possibility when all disease is resectable. Treatment strategies become 
complex for such patients and should be decided in a multi-disciplinary setting. 
1.1.1.1 Radiotherapy for Rectal Cancer  
Local recurrence (LR) rates are reduced when radiotherapy is used in addition to surgery for 
rectal cancer, but there is no definitive evidence of survival benefit from randomised trials 
(11, 12). Radiotherapy is therefore given to improve patients’ quality of life, and indeed 
pelvic recurrence of malignancy is a morbid event. This must be balanced against the 
morbidity of the treatment; radiotherapy is therefore used selectively for patients with 
rectal cancer. 
Indications for neoadjuvant radiotherapy include locally advanced rectal cancer (LARC), 
usually defined as those tumours with a clinical T stage of T3 or greater by the American 
Joint Committee on Cancer (AJCC) Tumour Node Metastasis (TNM) staging system, 
radiological suspicion of mesorectal lymph node involvement, a threatened circumferential 
resection margin (CRM), or tumours close to the anorectal margin traditionally necessitating 
abdomino-perineal resection. Common contraindications to radiotherapy include prior 
pelvic radiation or patient factors such as co-morbidity and frailty. 
Radiotherapy is given with or without low-dose chemotherapy as a radiosensitiser, and may 
be given pre-operatively or post-operatively. Two main neoadjuvant treatment strategies 
exist for rectal cancer, termed ‘short-course’ or ‘long-course’. ‘Short-course’ radiotherapy 
(SCRT) consists of 25 Gray delivered in five fractions over five days with rectal resection 
usually performed within 7-10 days. Chemotherapy is not given concurrently.  ‘Long-course’ 
(nCRT) regimens vary but a typical regimen consists of 45 Gray whole pelvis irradiation and a 
5.40 Gray boost to the tumour, delivered in 28 fractions over five and a half weeks. It is 
usually given with fluoropyrimidine-based chemotherapy (i.e. oral capecitabine or infusional 
5-fluoruracil) unless there are contraindications. Fluoropyrimidine therapy has been 
demonstrated to improve treatment response (13); there is equivalence between 
capecitabine and 5-FU (14). The interval after nCRT to surgery has historically been at least 6 
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weeks but there is evidence a longer interval improves pathological response (15), with 
some surgeons now waiting 12 weeks or longer post-nCRT prior to operating. 
There is evidence to support both SCRT and nCRT regimens as neoadjuvant therapy for rectal 
cancer. SCRT reduces LR compared with no neoadjuvant treatment (16), and an Australasian 
randomised trial found no significant difference in LR between SCRT and nCRT in T3N0-2M0 
rectal cancer patients (17). nCRT may have a greater reduction in LR in some circumstances 
(17), and there is a trend to favour nCRT when an optimal response is necessary to increase 
the chance of an R0 resection (for example a threatened circumferential resection margin) 
(18), particularly in younger fitter patients who will tolerate the additional therapy. pCR 
rarely occurs in SCRT with early surgery (rates 0-1.7%), but with an interval to surgery of 4-6 
weeks this increases to rates almost comparable with nCRT (11.8-15%) (19-21). There is 
significant variation in the ratio of SCRT to nCRT regimens used across New Zealand and the 
world. 
Post-operative radiotherapy is an alternative to pre-operative radiotherapy, although the 
evidence to support it is not as strong and as a result it tends to be used when it was not 
possible to deliver pre-operative radiotherapy (22). Evidence suggests the reduction in LR is 
greater with pre-operative treatment (13% compared with 6%) and late radiation toxicity is 
less (23); pre-op SCRT has been found to have lower LR rates than post-operative 
chemoradiotherapy (CRT) (24). Although the optimal regimen remains controversial, it is 
apparent that radiotherapy should be given pre-operatively if possible. 
Radiotherapy has significant morbidity associated with it, including early and late effects. 
Early toxicity includes skin erythema, diarrhoea and pain. Late effects include bowel 
obstruction, altered bowel habit, faecal incontinence and faecal urgency, and sexual 
dysfunction (25). There are specific socioeconomic implications for patients receiving 
radiotherapy for rectal cancer in New Zealand. Radiotherapy services are concentrated in 
major centres, with two radiotherapy centres in the South Island servicing that vast 
geographical area. Patients from rural areas can spend up to six weeks away from home in 
order to receive radiotherapy treatment and socioeconomic barriers may prevent some 
patients from receiving optimal treatment. Maori are slightly more likely to live rurally, and 
this additional barrier could perpetuate health disparities for Maori patients with rectal 
cancer. 
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1.1.1.2 Pathological Response to nCRT 
There is a highly variable pathological response to nCRT for rectal adenocarcinoma; up to 
20% of patients have a pathological complete response (pCR), 20-38% demonstrate either 
tumour progression or negligible regression and the remainder experience a significant 
(>50%) but incomplete response (26). A pCR occurs when no residual adenocarcinoma can 
be identified in the resection specimen after total mesorectal excision (TME) following 
neoadjuvant treatment, designated ypT0N0 by the AJCC staging system. This is recognised as 
a good prognostic factor and a survival advantage has been demonstrated in this group 
compared to those without pCR (27). It is probable that those who obtain a moderate 
response also obtain some benefit, especially if a previously threatened CRM is no longer 
threatened. Patients who experience negligible regression are unlikely to obtain benefit 
from neoadjuvant radiotherapy, and some patients may even be harmed as local and distant 
control of malignancy may be compromised.  
There are numerous systems described to assess the histological tumour regression grade 
(TRG) of rectal cancer following radiotherapy (28), the most widely used systems are 
presented Table 1.1. Tumour regression grading systems often consider only disease 
remaining in the bowel wall, not lymph node involvement. Tumour regression grading is 
generally accepted as the optimal outcome measure of disease response although no system 
is perfect; down-staging is likely to be a less reliable measure of disease regression given 
sub-optimal accuracy of clinical staging. 
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Table 1.1. Tumour regression grade systems (modified from reference (28)) 
 Dworak Mandard Ryan AJCC 
Complete 
regression 
No tumour cells 
(TRG 4) 
No residual cancer 
cells (TRG 1) 
No viable cancer 
cells, or single cells, 
or small groups of 







Very few tumour 
cells (TRG 3) 
Rare residual cancer 
cells (TRG 2) 









changes with few 
tumour cells or 
groups (TRG 2) 
Predominant fibrosis 
with increased 
number of residual 
cancer cells (TRG 3) 
Residual cancer 











mass with obvious 





outgrown by cancer, 
or no fibrosis with 
extensive residual 
cancer (TRG 3) 
Minimal or no 
tumour cells 





No regression (TRG 
0) 




Theoretically the ability to predict a poor response to nCRT could allow omission of the same 
if lack of benefit is also demonstrated in clinical studies, and patients could proceed directly 
to surgery. There is good evidence that pCR is associated with lower rates of local and 
distant recurrence (27); the impact of TRG on local recurrence has not been well studied but 
there is evidence that TRG is associated with local recurrence rates (29). Conversely, the 
ability to predict a complete clinical response (cCR) may support a trial of watch-and-wait 
(W&W) management.  
1.1.1.3 Watch-and-Wait Treatment of Rectal Cancer 
There is currently a significant shift occurring in rectal cancer treatment, with an increasingly 
prevalent view towards organ preservation using a W&W strategy after CRT as a viable 
alternative to surgical resection. The use of W&W relies on a cCR being achieved. This 
development may be the single biggest advancement in rectal cancer treatment in decades. 
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CRT is traditionally used in the neoadjuvant setting, although in some cases CRT is now being 
delivered with curative intent. A cCR occurs when there is no identifiable tumour remaining 
(intra-luminally or extra-luminally) on clinical examination, endoscopic or imaging 
assessment. 
Major advancement in W&W treatment of rectal cancer is largely due to the work of Habr-
Gama and colleagues in Brazil who first published their landmark paper in 2004 (30), but 
W&W now has significant uptake in centres of excellence worldwide (31, 32). The omission 
of early surgery may risk missing the chance of cure for loco-regionally confined malignancy, 
and death from rectal cancer progression may result. The benefits of omitting surgery are 
that the morbidity and mortality risks of rectal resection are avoided. Embarking on W&W is 
a complex decision that must consider patient and disease factors; rectal resection (with or 
without neoadjuvant treatment) remains the standard of care for rectal cancer at the 
current time. W&W should only be performed with input from a specialist centre with multi-
disciplinary agreement and extensive discussion with the patient, ideally in a clinical trial or 
international registry. 
Organ preservation is standard practice for some cancers including bladder and breast 
cancer, but these have major differences to rectal cancer. Breast cancer in particular has 
experienced a progressive reduction in the aggressiveness of surgery over decades. Breast-
conserving surgery and axillary node sampling is now routine for many patients with breast 
cancer; the highly morbid total mastectomy and axillary node dissection which was 
performed routinely historically is now reserved for selected cases.  The avoidance of high-
morbidity surgery should be the goal of all surgeons, provided oncological outcomes are not 
compromised. 
The role of additional chemotherapy after a cCR to CRT remains a controversial but 
developing area. Along with the rise of W&W we are also seeing alternative treatment 
strategies including total neoadjuvant treatment (CRT and chemotherapy) with significant 
increase in rates of pCR (33), with or without deferral of surgery if a cCR is achieved. 
W&W management of rectal cancer is a major developing field but there are still major 
barriers that need to be overcome if W&W is to become standard of care for a significant 
proportion of rectal cancer patients. These include accurately predicting which patients are 
likely to respond to CRT (optimising patient selection), optimising treatment response to CRT 
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by delivering the most effective treatment regimen, accurately assessing the clinical 
response to CRT, closely monitoring for early identification of loco-regional recurrence and 
effectively treating recurrence with salvage surgery while avoiding additional risk of 
mortality and morbidity over early resection.  
1.1.1.4 Summary and Outline of Thesis 
This thesis is focused on predicting the pathological response to nCRT for rectal cancer. The 
pathological response to nCRT is highly variable, with pCR rates ranging from 10-40%, and 
poor response rates of up to 40% (26). The exact reasons for differing response rates are 
unclear but is likely a combination of patient and disease characteristics, treatment regimens 
and outcome measures such as methods used to grade response. Predicting response is a 
critically important aspect of cancer treatment as it allows the avoidance of morbid and 
resource-demanding treatment in patients unlikely to benefit. There are clinical benefits to 
predicting good and bad responders to any treatment, but surgery and radiotherapy for 
rectal cancer carries significant morbidity and mortality risk only deemed acceptable in the 
pursuit of prolonging quantity or quality of life. The acceptability of such treatment in 
patients predicted to have low rates of response would be seriously questioned. An 
understanding of the impact of different predictors on pathological response would allow an 
increased understanding of the reasons for the different response rates observed. 
The remainder of chapter one includes a comprehensive systematic review of predictors of 
pathological response to nCRT for rectal cancer. This demonstrates current methods of 
prediction are blunt tools at best, and better predictors are needed to effectively personalise 
treatment. 
Chapter 2 reports a retrospective study examining clinical predictors in a five year cohort of 
patients treated with nCRT and TME at Christchurch Hospital, and describes an attempt to 
develop a simple clinical scoring tool based on predictors identified. Limited predictive ability 
of clinical predictors lead on to theorisation of a novel biomarker approach in chapter 3, a 
literature review exploring the role of oxidative stress in tumour cell death from 
radiotherapy and the potential role of endogenous antioxidants, specifically the 
peroxiredoxin family of thiol-dependent proteins, in predicting response. A prospective pilot 
study assessing selected biomarkers of oxidative stress and mitochondrial function using 
laboratory techniques novel in translational research is reported in Chapter 4. 
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Chapter 5 is a summary of findings from this thesis and discussion of potential future 
strategies to predict the response to CRT for rectal cancer across all categories of predictors, 
including clinical, biomarker and radiological predictors. 
1.2 Predicting Pathological Response to Neoadjuvant Chemoradiotherapy 
for Rectal Cancer: a Systematic Review of the Literature 
1.2.1 Introduction 
Within the current paradigm of rectal cancer treatment, a reliable predictor of response to 
nCRT for rectal cancer would allow for better selection of patients to receive nCRT prior to 
rectal resection. If poor response was predicted it could be safely omitted, and the patient 
would be best to proceed directly to surgery. If a good or even complete clinical response 
was likely nCRT could be more strongly recommended, including for early tumours not 
routinely treated with nCRT in current clinical practice (e.g. stage I rectal cancer). In the 
evolving field of a W&W strategy for rectal cancer, predicting response to radiotherapy 
would allow early selection of patients who could embark on W&W. Pathological complete 
response is a robust and clinically important outcome measure and has been a major focus 
of the literature so far, but prediction of complete responders is arguably less important 
than prediction of poor responders in the current environment where nCRT is the standard 
of care for LARC and would likely be offered if a complete or moderate response was 
expected. Those with a predictably poor response are the patients in whom omitting nCRT 
might be most advantageous. 
There has been a large and rapidly increasing volume of research attempting to identify 
predictive markers of pCR in rectal cancer. Predictive markers for pathological response (PR) 
are classified into three groups: clinicopathological, radiological and biomarkers. A previous 
systematic review by Ryan et al provided a summary of the evidence for predictive markers 
for pCR up to 2015 (26) but since this review was published the literature has expanded 
rapidly and a follow-up review is appropriate. Given the potential benefit in identifying poor 
responders and the limitations of focusing solely on pCR, this review includes all articles 
assessing pathological response as an outcome rather than exclusively pCR. 
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1.2.2 Method 
A PubMed, Embase and Medline search was performed for 2008-2018. The PubMed search 
was based on text words rectal cancer, pathological response and neoadjuvant 
chemoradiation, filtered for humans and English language. An Embase and Medline search 
was constructed for rectal cancer.mp. or Rectal Neoplasms/ AND Neoadjuvant Therapy/ or 
Chemoradiotherapy.mp. AND path* response*.tw. limited to English and Humans, excluding 
review articles. The initial search criteria were intentionally broad and included an outcome 
of pathological response rather than exclusively pCR. Inclusion criteria required an outcome 
of pathological tumour response measured by either pCR or tumour regression grade (TRG), 
pre-treatment predictors examined in relation to pathological tumour response, treatment 
with fluoropyrimidine-based concurrent neoadjuvant chemoradiotherapy for rectal 
adenocarcinoma. TRG as a categorical variable was acceptable provided the classification 
method was defined and based on a recognised TRG. Exclusion criteria included using down-
staging as a sole measure of response to CRT, use of extended neoadjuvant chemotherapy, 
review articles and meta-analyses, and studies with less than 30 participants. The article 
selection process is outlined in Figure 1.1. The search strategy was finalised in consultation 
with a librarian to ensure the optimal strategy was used. The search process and article 
inclusion/exclusion was performed independently by JF and SR who then discussed 
discordance and agreed on exclusion or inclusion for each article where necessary. 
Mediation was not necessary. 
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Figure 1.1. Article selection process for the systematic review 
1.2.3 Results 
167 articles were included in the qualitative synthesis. 56 articles were published 
subsequent to the last systematic review first published in 2015, demonstrating significant 
growth of literature in recent years. Outcome measures used in the literature for this review 
were limited to pCR, good response (GR) by dichotomised TRG (dTRG), and TRG as an ordinal 
variable.  
Predictors were categorised as clinicopathological predictors, biomarker predictors or 
radiological predictors. Table 1.2 outlines sub-categories of predictors included in the 
review.  
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Table 1.2. Predictors of response to nCRT included in this systematic review. 
Clinicopathological 
predictors 
Biomarker predictors Radiological 
predictors 
Patient factors e.g. 
demographics, co-morbidity 
Tumour Protein expression (IHC) CT 
Histopathology Gene methylation MRI 
Clinical examination findings Cytogenetics PET 
Endoscopic findings Blood Serum peptides e.g. CEA 




Gene sequencing including 
microarrays/gene signatures 
Single nucleotide polymorphisms 
mRNA 
mi-RNA 
1.2.3.1 Clinicopathological Predictors 
Clinicopathological predictors include clinical examination and endoscopic findings, 
histopathology reports and information routinely reported during radiological staging of 
LARC. This includes papers dedicated to clinicopathological predictors as well as data 
extracted from biomarker and radiological studies. Clinicopathological predictors were 
mostly investigated in retrospective studies. There were three notable database studies that 
were significantly larger than all other studies, those by Probst et al (34), Lorimer et al (35) 
and Al-Sukhni et al (36), with 18,113, 27,532 and 23,717 patients included respectively.  
1.2.3.1.1 Patient Factors 
Gender as a predictor of PR has been examined in a large number of retrospective studies 
which have shown no difference (37-48), although two large database studies found a small 
but significantly increased chance of pCR in females with an OR 1.24 (1.09-1.41, p=0.002) 
(34)  and OR 1.12 (1.03-1.22, p=0.0078) (49). 
Diabetes mellitus has been suggested as a negative predictor of pCR in a single retrospective 
study, with 0/17 diabetics achieving pCR compared with 21/93 (23%) non-diabetics (50), 
although Huh et al found no significant difference for pCR rate in diabetics on multivariate 
analysis (51). Increased body mass index (BMI) has been associated with poorer TRG (52) but 
several retrospective studies (n=242 to n=885) have reported no difference for pCR (37, 38, 
48, 51).   
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1.2.3.1.2 Histopathology 
Table 1.3 presents histopathological factors identified on pre-treatment biopsy. For 
differentiation, five of six studies found no significant difference while one study found poor 
differentiation was associated with a lower rate of pCR (53). Poor differentiation coupled 
with a T4 primary tumour predicted extreme unresponsiveness to nCRT in a Chinese 
population (54). 
Probst et al found an OR of 0.15 (0.10–0.28, p<0.001) for pCR for mucinous tumours (34), 
consistent with a previous systematic review and meta-analysis (55). Two studies found a 
trend without statistical significance for poorer response if mucinous histology is present; 
there was a low incidence of mucinous tumours in those papers (54, 56). One study 
suggested higher response rate with signet ring type but this is a rare cancer and numbers 
were small (57); Probst et al found a trend only (34). A single study suggested pCR is unlikely 
if tumour budding is present as a pCR was achieved in 0/18 patients with tumour budding 
(58), but the result was not statistically significant and tumour budding has rarely been 
reported for histopathology of biopsies historically. Few studies have examined 









Table 1.3. Histopathological predictors of pathological response to nCRT for rectal cancer. 
Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
Differentiation categories  
Grade 1-3 215 TRG NS - Retrospective (56)  
Well/moderate/poor 274 pCR NS Y Retrospective (60)  
Well/moderate/poor 121 dTRG NS - Retrospective (39) 
Well/moderate/poor 168 pCR NS - Retrospective (41) 
Well/moderate/ 
poor/undifferentiated 
23,747 pCR Poor differentiation OR 0.78 
(0.63-0.96) c.f. well 
differentiated, p=0.002  
Y Retrospective (53) 
Well-differentiated/ not 
well differentiated 
86 dTRG NS Y Retrospective (45)  
Mucinous histology 18,113 pCR OR 0.15 (0.10, 0.28), p<0.001 Y Retrospective (34)  
 248 pCR NS Y Retrospective (57)  
 168 pCR NS - Retrospective (41) 
 96 pCR NS  - Retrospective (54) 
 215 TRG NS - Retrospective (56) 
Signet ring histology 248 pCR RR 10.07 (2.47-41.10), 
p=0.001.  
Y Retrospective (57) 
 18,113 pCR NS Y Retrospective (34)  





1.2.3.1.3 Endoscopic and Examination Findings 
Table 1.4 presents endoscopic and examination findings investigated as predictors, the main 
findings of which are summarised in the following text. 
1.2.3.1.3.1 Distance to the Anal Verge  
Distance to the anal verge has been investigated in 12 studies as both continuous and 
categorical variables. Three studies found a significant difference in response rate but a wide 
range of measures were used using different categorisation of distance (Table 1.4). The 
studies were in agreement that a greater distance is likely to be associated with better 
chance of GR but this evidence is moderately weak. Distance to the anal verge should be 
measured using rigid sigmoidoscopy (61), but is often assessed clinically using digital rectal 
examination or flexible endoscopy; it is hence likely to be variably recorded and of limited 
accuracy. Distance to the anorectal margin on MRI is a more reproducible measure of 
position in the rectum that may be routinely included in synoptic reports, although arguably 
less clinically important due to limited accuracy of this measure also. 
1.2.3.1.3.2 Tumour Size 
Tumour size has been reported as a continuous and categorical variable, reported in eight 
studies. One study identified it as a predictor as a continuous variable with larger tumours 
less responsive (62), one suggested >5cm size is predictive of not achieving pCR (63). 
Although this evidence is mixed, the largest review of 23,747 patients found increasing size a 
significant predictor of poor response (53). Based on this evidence, increasing size appears 
associated with poorer response. 
Tumour site has been investigated in one study which found no difference in pCR for 
anterior compared with posterior tumours (41). Guedj found tumours are more often flat in 
responders but was the only study to assess this (64); flatness is an unusual description and 
may be a surrogate of total tumour volume. Absence of macroscopic ulceration was a 
predictor of pCR in one study (51). Weak evidence supports tumour mobility as associated 
with better pathological response (42, 65). Two out of four studies of circumferentiality 
found no association with pCR (41, 42), with only one suggesting non-circumferentiality 







Table 1.4. Endoscopic and examination predictors of pathological response to nCRT for rectal cancer 
Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
DTAV 
<4cm, 4-6cm, 6-8cm, 8-
10cm, >10cm  
827 pCR 4-6cm OR 2.54 (1.36-4.75), 6-
8cm OR 2.55 (1.37-4.74) c.f. 
<4cm, p=0.008 
Y Prospective (66) 
≤6 or >6cm 98 dTRG NS Y Prospective (65) 
>8cm or ≤ 8cm  99 pCR NS - Retrospective (63) 
>5cm or ≤5cm 249 pCR NS  - Retrospective (42)  
>5cm or ≤5cm 260 pCR >5cm OR 3.82 (1.60-8.70), 
p=0.02 
Y Retrospective (67)  
≥5cm or <5cm 95 pCR NS -  (59)  
Low/medium/high 168 pCR NS - Retrospective (41) 
Continuous variable 242 pCR NS - Retrospective (38) 
Continuous variable 274 pCR NS - Retrospective (60) 
Continuous variable 885 pCR OR 1.07 (1.01-1.15), p=0.04 Y Retrospective (37) 
Continuous variable 620 pCR NS Y Retrospective (48) 
Macroscopic ulceration 
(absence of) 
391 pCR OR, 6.70 (2.04-22.07), p=0.002 Y Retrospective (51) 
Circumferentiality 
Non-circumferentiality 391 pCR OR 3.21 (1.38-7.50), p=0.007 Y Retrospective (51) 
Circumferentiality 98 dTRG Increased circumferentiality 
had increased risk of poor 






Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
response, HR 2.39 (1.14-3.40), 
p=0.019 
Circumferentiality 168 pCR NS - Retrospective (41) 








23,747 pCR <1cm = reference, p<0.001 




 3.07 (2.27–4.14) 





297 pCR NS for categorical analysis;  
pCR increased with decreasing 
tumour size OR 1.315 (1.018–
1.698), p=0.036 
Y Retrospective (68) 
>5cm/ ≤5cm 99 pCR ≤5cm OR 0.25 (0.1-3.44), 
p=0.035  
Y Retrospective (63) 
>5cm/ ≤5cm 121 dTRG NS - Retrospective (39) 
> 4/ ≤ 4 249 pCR NS  Y Retrospective (42) 
Continuous variable 391 pCR NS Y Retrospective (51)  
Continuous variable 168 pCR NS - Retrospective (41)  






Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
       
Tumour mobility 98 dTRG HR 2.65 (1.43-4.90), p=0.002 Y Retrospective (65) 
 
168 pCR NS - Retrospective (41) 
249 pCR OR 2.78 (1.14-6.78), p=0.024  Y Retrospective (42) 




1.2.3.1.3.3 Clinical TNM Staging 
Table 1.5 presents studies that have investigated clinical TNM stage as a predictor.  
Clinical tumour stage (cT) has been examined often and only three studies have 
demonstrated significant associations with pathological regression, however these included 
the two studies that were largest by far (49, 53) and both found T4 tumours were 
approximately half as likely to achieve pCR compared with T1-T3 tumours. These findings 
were supported by a third smaller study which compared T4 to T3 and found a similar effect, 
albeit with a small sample size and wide confidence interval (69). pCR appears significantly 
less likely for T4 tumours but the difference in response for lower T stage tumours does not 
appear as great. 
Clinical nodal stage (cN) was assessed either as a binary variable for nodal positivity (N0 vs. 
N1/2) or by categorical N stage (N0 vs. N1 vs. N2). Nodal positivity has been associated with 
poorer TRG (56, 69, 70) and lower rate of pCR (68, 71). Only one study found no difference 
for dTRG (45) but four studies found no difference for pCR. As an ordinal variable four 
studies found no difference and four studies found increasing cN stage was associated with a 
decreasing pCR rate, including Lorimer et al (49) and Al-Sukhni et al (53) with an OR of 1.6 
for pCR in N0 vs. N2 and a 30% reduction in pCR for N2 stage compared with N0 respectively. 
Nodal involvement appears to be a predictor of poor pathological response and this 







Table 1.5. Clinical TNM stage as a predictor of pathological response to nCRT for rectal cancer 
Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
Clinical T stage 
cT1/T2/T3/T4 
 
27,532 pCR T4 = reference, p<0.0001 
T1: OR 2.81 (1.80–4.40)  
T2: OR 2.72 (2.09–3.55) 
T3: OR 1.90 (1.55–2.33) 
Y Retrospective (49) 
cT1/T2/T3/T4 23,747 pCR T1 = reference, p=0.002 
OR for  
T2: OR 0.84 (0.63-1.12) 
T3: OR 0.80 (0.62-1.04) 
T4: OR 0.57 (0.42-0.78)  
Y Retrospective (53) 
cT1/T2/T3/T4 33 pCR NS - Retrospective (43) 
cT1/T2/T3/T4 469 pCR NS Y Retrospective (40) 
cT2/T3/T4 297 pCR NS - Retrospective (68)  
cT2/T3/T4 86 dTRG NS Y Retrospective (45) 
cT2/T3/T4 168 pCR NS  Retrospective (41) 
cT2 or cT3 /cT4  122 pCR NS Y Retrospective (71) 
cT2 or cT3 /cT4 274 pCR NS - Retrospective (60) 







Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
cT3/ cT4 148 Good 
response 
(dTRG) 
cT3 OR 2.762 (1.11-6.36), 
p=0.039 
Y Retrospective (69) 
 
cT3/cT4 98 dTRG NS Y Prospective (65)  
cT =3/MRF- / 
cT =3/MRF+ /  
cT =4 / 
cT=1–2 
620 pCR NS Y Retrospective (48) 
 
Clinical N stage 
cN+ or cN0 215 TRG cN+ poorer TRG, p=0.008 N Retrospective (56) 
cN+ or cN0 148 Good 
response 
(dTRG) 
cN0 OR 2.65 (1.14 – 6.52), 
p=0.034 
Y Retrospective (69) 
cN+ or cN0 609 Good 
response 
(dTRG) 
cN0 OR 1.91 (1.23-2.95), 
p=0.004 
Y Retrospective (70)  
cN+ or cN0 122 pCR cN+ negative predictor for 
pCR, with HR 3.701 (1.03 – 
13.26), p=0.044 
Y Retrospective (71) 
cN+ or cN0 297 pCR cN0 OR 4.4 (1.01 - 19.02), 
p=0.048 
Y Retrospective (68) 
cN+ or cN0 96 Good 
response 
(dTRG) 
cN0 OR 1.98 (1.04–4.80), 
p=0.005 






Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
cN+ or cN0 86 dTRG NS Y Retrospective (45) 
cN+ or cN0 168 pCR NS  Retrospective (41)  
cN+ or cN0 274 pCR NS - Retrospective (60) 
cN+ or cN0 885 pCR NS  Y Retrospective (37) 
cN+ or cN0 391 pCR NS Y Retrospective (51) 
cN0/N1/N2 242 pCR NS Y Retrospective (38)  
cN0/N1/N2 99 pCR NS Y Retrospective (63) 
cN0/N1/N2 33 pCR NS - Prospective (43) 
cN0/N1/N2 469 pCR NS Y Retrospective (40) 
cN0/N1/N2 55 pCR cN lower in pCR, p = 0.002 N Retrospective (73) 
cN0/N1/N2 620 pCR cN0 = reference, p=0.04 
cN1: OR 3.42 (1.03–11.32) 
cN2: OR 4.52 (1.32–15.55) 
Y Retrospective (48) 
cN0/N1/N2 23,747 pCR cN0 = reference, p=0.014 
cN2: OR 0.71 (0.56–0.89) 
cN1: OR 0.97 (0.88–1.07) 
Y Retrospective (53) 
cN0/N1/N2 27,532 pCR cN2 = reference, p<0.0001 
cN0: OR 1.62 (1.35–1.94)  
cN1: OR 1.41 (1.17–1.69) 
Y Retrospective (49) 




1.2.3.2 Biomarker Predictors 
Biomarkers have been extensively investigated with a large number of potential candidates 
identified. Biomarkers can be either tissue or blood based and have been previously 
categorised in Table 1.2.  
1.2.3.2.1 Carcinoembryonic Antigen (CEA) 
CEA as a predictor of pCR has been the subject of a systematic review and meta-analysis 
published in 2017 which concluded CEA was inversely correlated with probability of pCR 
(74). The evidence found in the current review is summarised in Table 1.6, and studies 
published subsequent to the meta-analysis appear unlikely to change the conclusions of that 
paper. Most studies have found lower CEA is associated with pCR and GR, either as a 







Table 1.6. CEA as a predictor of pathological response to nCRT for rectal cancer 
CEA classification n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
Continuous variable 
(ng/mL) 
885 pCR OR 1.03 (1.01-1.06), p=0.03  Y Retrospective (37) 
Continuous variable (log2 
ng/mL) 
620 pCR OR 0.861 (0.743-0.999), p=0.049 Y Retrospective (48) 
Continuous variable 
(ng/mL) 







5.62 vs. 22.27 ng/mL, p=0.002; 
6.30 vs. 27.86 ng/mL, p<0.001 
N Prospective (76) 
Continuous variable 
(ng/mL) 
148 dTRG NS Y Retrospective (69) 
Continuous variable 
(ng/mL) 
73 pCR NS   - Retrospective (77) 
Elevated 18,113 pCR OR 0.65 (0.52–0.77), p<0.001 Y Retrospective (34) 
Elevated 23,747 pCR NS 
 
Y Retrospective (53) 
≤2.5 ng/ml 
 
148 pCR Associated with higher pCR rate N Retrospective (78) 
<2.5/ ng/mL / ≥2.5 ng/mL 242 pCR NS Y Retrospective (38) 
≤3/3–6/ 6–9 ≥9 352 Good 
response 
(dTRG) 
≤3 = reference, p<0.001 
3-6: OR 0.34 (1.124-0.919) for 6-
9: OR 0.15 (0.058-0.401) 






CEA classification n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
≤5ng/mL 274 pCR Predicted pCR if <5ng/mL, no OR 
given 
Y Retrospective (60) 
>5ng/mL 469 pCR OR 0.90 (0.81–1.00), p=0.04 Y Retrospective (40) 
≤5ng/mL 609 dTRG OR 2.53 (1.63-3.92), p<0.001 Y Retrospective (70) 
≤5ng/mL 212 pCR NS   - Retrospective (80) 
<5ng/mL 86 dTRG NS Y Prospective (45) 
<5ng/mL 391 pCR OR 2.66 (1.38-5.12), p=0.004 Y Retrospective (51) 
<5ng/mL 351 pCR OR 3.08 (1.29-7.37), p=0.011 Y Retrospective (81) 
<5ng/mL 260 pCR OR 9.32 (2.16–40.19), p=0.03 Y Retrospective (67) 
<5ng/mL 168 pCR NS Y Retrospective (41)  




Dreyer et al investigated the validated SIRS marker modified Glasgow Prognostic Score 
(mGPS) which is calculated by assigning a score of one each for an elevated C-reactive 
protein and hypoalbuminaemia and found mGPS pre-CRT was a strong independent 
predictor of GR on logistic regression (44). 
1.2.3.2.2 Haematological Predictors 
In two of six studies increasing haemoglobin was associated with pCR. In both studies it was 
assessed as a continuous variable without a defined cut-off. A real difference is possible but 
the clinical significance of this is not likely to be large. Circulating lymphocyte ratio (82) and T 
helper and cytotoxic T cells (47) have been associated with GR in small retrospective studies. 
Fibrinogen levels were associated with pCR [OR 2.026 (1.369-2.997), p<0.001] in a single 
study of 947 patients (75). Multiple studies have examined the neutrophil to lymphocyte 
ratio and none found it predictive of PR (44, 77, 82-85). Sun et al found no association 







Table 1.7. Haematological parameters as predictors of pathological response to nCRT for rectal cancer 
Predictor n Outcome 
measure 
Findings 
OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
Haemoglobin 
Continuous variable 573 pCR OR 1.30 (1.10–1.53), p=0.002 Y Retrospective (48) 
Continuous variable; 
anaemia 
173 pCR OR 1.04 (1.00–1.07), p=0.05; 
anaemia NS 
Y Retrospective (83) 
Continuous variable 73 pCR NS - Retrospective (77)  
Continuous variable 885 pCR NS  Y Retrospective (37) 
Continuous variable / 
Hb < 12 g/dl or ≥ 12 
g/dl 
464 pCR NS Y Retrospective (87) 
Normal/ Anaemia 79 dTRG NS - Retrospective (44) 
Circulating lymphocytes 85 pCR; dTRG pCR NS; lymphocyte ratio ≤24.6% OR for good 
response 3.99 (1.37-8.28), p<0.01  
Y Retrospective (82) 
45 dTRG Th and Tc independent predictors of good response 
HR = 10.56 (1.5-99.6) and 11.38 (1.5-146.4, 
p=0.0194) respectively, p=0.0124 
Y Prospective (47) 
Red blood cells 173 pCR NS Y Retrospective (83) 
Platelets 173 pCR NS Y Retrospective (83) 
314 pCR <370,0000/uL predictor pCR OR 5.483 (1.27–23.65), 
p=0.023 
Y Retrospective (81) 
Th = T helper cell; Tc = cytotoxic T cells 
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There is some evidence of a difference between sub-types of TILs in responders and non-











OR (95% CI), p value 
Multivariate 
analysis 
Study Design Reference 
31 dTRG Low density CD8+ TILs associated with poor response N Retrospective (88)  
106 TRG NS - Retrospective (89) 
128 pCR; TRG OR 5.27 (1.62-17.16), p=0.0058 for pCR with low Foxp3 expression; 
association with TRG on univariate analysis only. 
Y Retrospective (90) 
62 dTRG Good responders had higher CD81TILs and CD41TILs, and lower MDSC-
TILs (high vs low CD81TILs 61.2% vs 32.2%; p=0.022; high vs low 
CD41TILs 61.2% vs 32.2%; p=0.022; high vs low MDSC-TILs 29.0% vs 
64.5%; p=0.005) 




1.2.3.2.3 Protein Expression 
A large number of protein biomarkers have been evaluated as predictors of response to 
radiotherapy for rectal cancer. Due to the vast amount of material in the literature, those 
that have been assessed in more than one study are presented in this section and Table 1.9, 
and those assessed only in a single study are listed in the appendix (Table A1). Although 
other methods are available (either antibody or spectrometry based), generally protein 
expression is assessed using immunohistochemistry (IHC) with antibody-based detection of 
the protein of interest on a formalin-fixed paraffin-embedded (FFPE) slide, often 
retrospectively. Any one of a number of scoring systems may be used to semi-quantitatively 
analyse IHC (92). The advantages of IHC include being able to use historical diagnostic FFPE 
slides without a need to prospectively obtain tissue and process in a specific manner. It is a 
technique used routinely in pathological practice and therefore holds potential for easy 
translation to clinical use. It can also be done with relative efficiency including automated 
staining allowing relatively large numbers of samples to be processed compared with 
manual methods such as gel electrophoresis and immunoblotting. It is usually relatively 
sensitive and specific although this is antibody dependent.  Disadvantages include variability 






Table 1.9. Protein expression assessed using immunohistocheistry as predictors of pathological response to nCRT for rectal cancer 
Predictor n Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
Ki67 81 pCR High expression OR 4.48 (1.43-14.09), p=0.01 Y Retrospective (73) 
60 Good response 
(dTRG) 
OR 1.17 (1.06-1.29), p=0.002 Y Retrospective (93) 
55 pCR; dTRG NS; Good responders lower expression (70.7% vs. 28.5%, 
p<0.001) 
N Retrospective (94)  
46 pCR NS Y Retrospective (95)  
40 dTRG NS - Retrospective (64) 
130 dTRG NS Y Retrospective (96) 
70 TRG NS - Retrospective (97) 
86 TRG NS - Prospective (98) 
37 TRG NS - Retrospective (99) 
112 TRG NS Y Retrospective (100)  
Bax 
 
60 Good response 
(dTRG) 
OR 18.1 (3.11-105.7), p=0.001 Y Retrospective (93) 
152 pCR; dTRG NS - Retrospective (101)  
 pCR NS - Retrospective (73) 
Bcl-2 130 dTRG Correlated with tumour regression Y Retrospective (96) 
152 pCR; dTRG NS - Retrospective (101)  
86 TRG NS - Prospective (98) 





Predictor n Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
COX-2 82 pCR Low Cox-2 expression gave a HR of pCR of 0.205 (0.059-
0.708), p=0.012 
Y Retrospective (102) 
55 pCR; dTRG NS; Good responder’s lower expression (72.9% vs. 22.8%, 
p<0.001) 
N Retrospective (94)  
152 pCR; dTRG NS; high Cox-2 expression correlated with poor response  N Retrospective (101)  
30 TRG NS Y Prospective (103)  
130 dTRG NS y Retrospective (96) 
 pCR NS - Retrospective (73) 
p21 112 TRG high expression associated with poor pathologic responses 
OR of good response 0.127 (0.022-0.729), p=0.021 
Y Retrospective (100) 
70 TRG NS - Retrospective (97) 
152 pCR; dTRG NS - Retrospective (101)  
 
81 pCR High expression OR 4.65 (1.50-14.46), p=0.008 Y Retrospective (73) 
p53 70 TRG NS - Retrospective (97) 
130 dTRG NS Y Retrospective (96) 
37 TRG NS - Retrospective (99) 
152 pCR; dTRG NS - Retrospective (101)  
121 dTRG P53 type on IHC was positively correlated with response 
(p=0.039) 
Y Retrospective (39) 
81 pCR NS Y Retrospective (73) 





Predictor n Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
 pCR NS - Retrospective (73) 
VEGF 152 pCR; dTRG NS; High VEGF expression correlated with poor response  Retrospective (101)  
46 pCR NS Y Retrospective (95)  
55 pCR NS - Prospective/ 
Retrospective 
(104)  
85 TRG NS - Retrospective (105) 
81 pCR High expression OR 4.34 (1.24-15.11), p=0.02 Y Retrospective (73) 
TS 46 pCR High TS expression OR 16.7 (1.8-150.9), p=0.002 Y Retrospective (95)  
60 Good response 
(dTRG) 
OR 1.83 (1.11-3.03), p=0.019 Y Retrospective (93) 
 pCR NS - Retrospective (73) 
GLUT1 40 dTRG NS - Retrospective (64) 
 
86 TRG NS - Prospective (98) 
85 TRG NS - Retrospective (105) 
104 pCR; TRG pCR rate 27.8% in low expression vs. 4.0% in high 
expression group, p=0.012 
N Retrospective (106) 
HIF-1α 104 pCR NS - Retrospective (106) 
86 TRG NS - Prospective (98) 
85 TRG NS - Retrospective (105) 
180 Good response 
(dTRG) 





Predictor n Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
55 pCR NS - Prospective/ 
Retrospective 
(104)  
HER2 130 dTRG NS Y Retrospective (96) 
119 TRG NS - Retrospective (108) 
APAF-1 152 pCR; Good 
response (dTRG) 
NS; strong correlation between high APAF-1 expression 
and good response  
- Retrospective (101) 
 
82 pCR low expression HR 4.29 (1.34-13.70), p=0.014 Y Retrospective (102) 
Survivin 36 dTRG NS - Retrospective (109)   
43 Good response 
(dTRG) 
8/26 response in high expression vs. 11/17 in low 
expression group, p=0.01 
N Retrospective (110) 




Nine studies have assessed Ki67 protein staining by IHC with outcomes of pCR and TRG; 
three studies found a difference in expression but they were not all concordant, two found 
higher expression of Ki67 protein associated with better response (73, 93) while the third 
found lower expression associated with GR (94).  
Bax and Bcl-2 are markers of apoptosis. Kikuchi et al found better TRG was associated with 
higher expression of Bax on multiple logistic regression in 60 patients (93), but two other 
studies found no difference (73, 101). One of four studies found positive Bcl-2 staining 
correlated with poorer dTRG in 130 patients (96). APAF-1 and survivin are also regulators of 
apoptosis. Two studies of APAF-1 found associations between high APAF-1 expression and 
GR (101), and high APAF-1 expression and pCR (102). Of three studies investigating survivin 
two found no difference (99, 109); a third study found better response with lower 
expression but only included 43 patients (110). 
COX-2 is an isozyme of cyclooxygenase (COX), an enzyme responsible for synthesis of 
prostaglandins and thromboxane from arachidonic acid. COX inhibitors may prevent or slow 
the development of colorectal neoplasia (111). Three studies found lower expression 
associated with GR and three studies found no difference. Although these are small studies, 
any true directional association is unlikely to be strong. 
p21 is a cell cycle regulator. Sim et al found high expression of p21 was associated with 
poorer TRG (100), while Hur et al found higher p21 expression had increased pCR rates 
compared with low expression (73). Two studies found no difference and overall it can be 
said no evidence of a directional effect exists. The p53 tumour suppressor gene protein 
product was examined in six studies, with five finding no significant difference although one 
study found p53 wild-type was associated with GR when compared to mutant p53 (39).  
Epidermal growth factor receptor (EGFR) is a key molecule involved in the MAPK/ERK 
pathway of colorectal carcinogenesis, and is the target of monoclonal antibody therapy with 
clinical utility in metastatic colorectal cancer. Low EGFR expression was associated with pCR 
in one study, another found no difference. Vascular endothelial growth factor (VEGF) has a 
known role in angiogenesis which is required for tumour growth. No association between 
VEGF expression and pathological response was found in three studies; high expression was 
associated with poorer TRG in a single study (101).  
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GLUT1 and HIF-1α are markers of cellular hypoxia. Multiple studies showed no significant 
difference for TRG or pCR for either marker (64, 98, 104-106), with one small study showing 
an association with each marker on univariate analysis only (106, 107).  
1.2.3.2.4 Gene Expression Profiling 
Gene expression involves DNA sequencing using methods such as real time quantitative 
polymerase chain reaction. It can be performed on tumour or germline tissue. Predictors 







Table 1.10. Gene expression profiling as predictors of pathological response to neoadjuvant chemoradiotherapy for rectal cancer 
Predictor Tissue 
sequenced 
n Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
KRAS Tumour 146 TRG NS - Retrospective (112) 
Tumour 132 pCR KRAS mutations more common in 
non-pCR (49% versus 24%, p=0.0145) 
N Prospective (113)  
Tumour 96 pCR; TRG NS - Prospective (114) 
CCND1  Tumour 132 pCR Mutations more common in non-pCR N Prospective (114) 
MTHFR Tumour 132 pCR Mutations more common in non-pCR N Prospective (113) 
P53 Tumour 96 pCR; TRG NS - Prospective (114) 
EGFR Tumour 46 pCR Low EGFR associated with pCR 
(p=0.007)  
Y Prospective (95) 
EGFR Tumour 146 TRG NS - Retrospective (112) 
EGFR Tumour 40 dTRG NS Y Retrospective (115) 
EGFR  Germline 93 dTRG NS - - (116). 
VEGF Tumour 40 dTRG Low VEGF associated with good 
response. Hr 30.25 (1.72-529.68) 
P=0.019 
Y Retrospective (115) 
HIF1 Tumour 40 dTRG NS Y Retrospective (115) 
Clock, Cry2 and 
Per2 (circadian 
clock genes) 
Tumour 40 pCR Expression of all significantly higher in 
pCR (p<0.05) 
N Retrospective (117) 
PI3K pathway Tumour 201 pCR Wild-type pathway  
OR 5.146 (1.17–22.58), p=0.030 c.f. 
mutated pathway 







n Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
MAPK pathway 
(RAS, BRAF, MEK) 
Tumour 201 pCR NS N Retrospective (43) 
RTK genes Tumour 201 pCR NS N Retrospective (43) 
XRCC1 Germline 93 dTRG Significant difference in 
polymorphisms for good and poor 
responders 
- - (116) 
ERCC1 Germline 93 dTRG NS - - (116) 
MTHFR Germline 93 dTRG NS - - (116) 
DPYD Germline 93 dTRG NS - - (116) 
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1.2.3.2.5 Thymidylate Synthase 
Thymidylate synthase (TS) is a key enzyme necessary for DNA synthesis, and is inhibited by 
5-FU. Alterations in the TS gene (germline or tumour) therefore could influence outcomes 
for patients by altering natural progression or response to 5-FU treatment commonly used in 
nCRT.  
Carlomagno et al found high TS expression on IHC associated with pCR (95), as did Kikuchi et 
al (93) but a third study found no difference. Hur et al found no significant difference in 
tumour regression for TS gene polymorphisms on tumour biopsy in 44 patients with rectal 
cancer (118). With regard to germline TS polymorphisms, a study of 50 patients found that 
having at least one TS 3G allele were more likely to have a complete or partial pathological 
response to 5-FU [OR 10.4 (1.3–81.6), p=0.01] (119). Paez et al also looked at germline TS 
polymorphisms for 51 patients over 9 years and found on logistic regression analysis only 
one genotype correlated with PR (120). Germline polymorphisms again examined by Paez et 
al found no relationship between the different TS genotypes and pCR in 128 patients (121). 
Tan et al examined germline TS polymorphisms in 135 patients and found no difference 
between pCR for different genotypes (122). Lamas et al found that TS polymorphisms 
differed between patients obtaining good and poor responses (116). 
1.2.3.2.6 Single Nucleotide Polymorphisms (SNPs) 
An SNP involves alteration of a single nucleotide at a specific position in a gene. Such minor 
alterations can have significant effects on gene expression and function. Numerous SNPs 
have been investigated in predicting response to CRT for rectal cancer; the affected genes 
containing SNPs with suggested predictive ability are presented in Table 1.11. Exact 






Table 1.11.  Single nucleotide polymorphisms as predictors of pathological response to nCRT for rectal cancer 




Findings (OR, 95% CI), p value Multivariate 
analysis 
Study Design Reference 
XRCC1 113 Germline pCR OR for non-pCR 3.24 (1.20–8.74), p=0.020 Y Retrospective (123) 
MSH6 113 Germline pCR OR for non-pCR 0.12 (0.03–0.51), p=0.004 Y Retrospective (123) 
VEGF-α 113 Germline pCR OR for non-pCR 3.14 (1.18–8.38), p=0.022 Y Retrospective (123) 
DROSHA 265 Germline pCR OR for non-pCR 1.87 (1.10-3.17), p=0.0207 Y Retrospective (123) 
TRBP 265 Germline pCR OR 0.39 (0.19-0.79), p=0.0089 Y Retrospective (123) 
SMAD3 (three 
SNPs) 
265 Germline pCR OR 2.01 (1.22-3.31), p=0.0064; OR 0.45 
(0.24-0.85), p=0.0135; OR 0.48 (0.25-0.94), 
p=0.0316 
Y Retrospective (123) 
SOD2 71 Germline dTRG OR 0.19 (0.06-0.64), p=0.005 Y Prospective (124) 
IL13 71 Germline dTRG OR 0.14 (0.04-0.49), p=0.0008 Y Prospective (124) 
IL13 46 Tumour dTRG NS - Retrospective (125) 
CORO2A (two 
SNPs) 
113 Germline dTRG OR 0.377 (0.18-0.789), p=0.01; OR 0.205 
(0.044-0.944), p=0.03 
N Prospective (126) 
AREG 84 Germline pCR OR 0.26 (0.06–0.79), p=0.0149 Y Retrospective (127) 
ERCC1 (two 
SNPs) 
84 Germline pCR OR 0.24 (0.05, 0.73), p = 0.0096; OR not 
estimable p=0.0238 
Y Retrospective (127) 
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1.2.3.2.7 Microarrays and Gene Signatures 
Microarrays allow a large number of genes to be sequenced at one time, consisting of a large 
number of probes attached to a solid surface with subsequent quantification of the 
abundance of specific nucleic acid sequences targeted. Such an approach has experienced 
some success in predicting response to chemotherapy for breast cancer (128).  Several 
attempts to use microarrays to predict response to radiotherapy for rectal cancer have been 
attempted with very limited success (129). Rimkus et al generated gene expression profiles 
from 43 tumour biopsies and identified a 42 gene expression signature but the positive 
predictive value for those identified as responders was only 71% (130). Gantt et al identified 
a 183-gene signature and an 812 gene signature for 33 patients (131).  The 812 gene 
signature had 100% sensitivity and specificity for non-responders while the 183 gene 
signature had 33% sensitivity and 100% specificity, but the limited generalisability of 
complex genetic profiling of small numbers of patients is unlikely to yield a clinically useful 
predictor with generalisability. 
1.2.3.2.8 Messenger RNA 
Gene expression is dynamic. Biological switches act to regulate gene expression according to 
biological need. When required, messenger RNA (mRNA) conveys genetic information from 
the nucleus to the ribosome to determine the amino acid sequence required for protein 
synthesis. Because cellular processes are complex, mRNA identified does not necessarily 
result in a protein being produced in meaningful amounts, and therefore it is different to 
detecting protein by IHC or other methods. mRNA molecules can be identified in tissue or 
serum, and numerous mRNAs have been explored as predictors of response to radiotherapy 
for rectal cancer. Each mRNA is likely to have a biological function specific to the protein it 
codes but the function of many mRNA molecules are not yet known. mRNA is generally 
sequenced using quantitative reverse transcription polymerase chain reaction. 
Huh et al looked at 13 mRNA biomarkers in 123 tumour biopsies and found elevated 
expression of CD44 was predictive of poorer TRG [OR 4.694 (1.155-17.741), p=0.030]; there 
was no difference for pCR (132). They found no difference for p53 or CD133, among others 
(132) while in contrast, Hur et al found mRNA expression for p53, p21, Ki67, and CD133 was 
significantly associated with GR and pCR, but there was no difference for CD44 (133). In both 
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this study and their 2014 study (73) they attempted to create a biomarker based scoring 
system with limited success (133). 
Decreased neuronal pentraxin 2 mRNA in 40 patients was associated with better TRG and 
pCR. Mean CXCL10 mRNA expression was significantly higher in non-PCR patients but there 
was no difference in CXCL10 protein expression by IHC in the same patients (59), making it 
less likely to be a truly significant biological effect. 
1.2.3.2.9 Micro-RNA 
Micro-RNA (miRNA) are small noncoding regions of RNA that have a role in regulation of 
gene expression (134). miRNA with suggested predictive potential are summarised in Table 
1.12. As with many novel biomarker studies, these are best considered pilot studies as they 
often include small numbers of patients and there is no clinical application at the current 







Table 1.12. Micro-RNA predictors suggested to have potential as predictors of pathological response to nCRT for rectal cancer 
miRNA n Source 
tissue 
Outcome Findings (OR, 95% CI), p value Multivariate 
analysis 
Reference 
miR-21 92 Tumour pCR High expression OR 9.75 (2.24 to 42), p=0.01 Y Carames, Cristobal (135)  
miR-31 82 Tumour dTRG Overexpression predicted poor response  OR 0.18 
(0.06 to 0.57), p=0.003 
Y (136)  




dTRG High expression associated with poor response N (137)  
miR-194 38 Tumour dTRG Significantly upregulated in responders N (138)  
miR-145 40 Tumour dTRG Major response correlated with higher 
expression (p=0.031) 
N (139)  
Set of 13 
miRNA 
38 Tumour pCR Strongly associated with pCR N (140) 






dTRG High expression correlated with poor response in 
tumour. 
miR-345 expression significantly downregulated 
in CRT-sensitive group (p=0.007) 
N (141)  
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1.2.3.2.10 Gene Methylation 
Methylation is a way of regulating gene expression according to biological need. Methylation 
of genes associated with radiosensitivity could therefore play a role in predicting response to 
nCRT. Ha et al explored the association of a selection of such genes with TRG and suggested 
methylation of KLHL34 may be predictive but the finding was of borderline statistical 
significance (142). Molinari et al examined methylation across a large number of genes in 74 
rectal cancer biopsies and found TIMP3 methylation was statistically different across four 
TRG classes on ANOVA, but the main difference appeared to be between Dworak TRG 1 
(minimal regression) and 2 (moderate regression) which is of limited clinical benefit (143). 
Tsang et al found global methylation in 53 rectal cancer biopsies correlated with a modified 
3-point TRG (p<0.001), with a significant difference between pCR and partial PR (144).  
1.2.3.2.11 Chromosomal Alterations 
A cytogenetics approach found tumour cell chromosomal alterations in 1p, 1q, 11p, 12p and 
17p were associated with grouped TRG in 45 patients (145). Higher rates of error in 
chromosome segregation enhanced pathological response in 62 patients [OR 3.9 (1.18-
12.91), p=0.02], and when combined with decreased levels of the DNA damage repair 
protein Mre11 portended a markedly enhanced response (OR 54.0, 95% CI not provided, 
p=0.008) (146). A cytogenetics microarray approach called ‘array Comparative Genomic 
Hybridization’ analysis of tumour biopsies in 48 patients found differences between a large 
number chromosomal alterations in responders vs. non-responders to CRT based on dTRG 
although the clinical application of this, like specific gene signatures of complex molecular 
panels, is not immediately realisable (147). 
1.2.3.3 Radiological Predictors  
Advanced imaging characteristics are considered in this category. These include any 
radiological parameters over and above routine clinical staging. Radiological modalities 
investigated in the period of this systematic review included computed tomography (CT), 
magnetic resonance imaging (MRI) and positron emission tomography (PET). CT texture 







1.2.3.3.1 Magnetic Resonance Imaging (MRI) 
Table 1.13. MRI parameters as predictors of pathological response to nCRT for rectal cancer 
Parameters assessed n Outcome Findings Multivariate 
analysis 
Study Design Reference 
ADC (dwMRI) 100 (n=50 
pCR, n=50 
non-pCR) 
pCR ADC poor predictor with AUC of ROC 
0.670 
N Retrospective (149) 
ADC (dwMRI) 76 pCR NS - Retrospective (150) 
ADC (dwMRI) 64 pCR NS - Prospective (151) 
ADC (dwMRI) 34 dTRG NS - Prospective (152) 
ADC, tumour volume 
(dwMRI) 
59 pCR ADC lower in pCR group (p=0.010). AUC 
of ROC was 0.77 for predicting pCR 
N Prospective (153) 
ADC histogram analysis 
(dwMRI) 
86 pCR NS 
 
N Retrospective (154) 
ADC, pseudodiffusion (D*) 
coefficient, true diffusion 
coefficient (D), perfusion-
related fraction (f). 
(T2/dwMRI) 
98 pCR NS - Prospective (155) 
Dapp, Kapp and ADC 
(T1/T2/dwMRI/DCE MRI) 
41 dTRG Dapp-10th lower in good responders than 











Parameters assessed n Outcome Findings Multivariate 
analysis 
Study Design Reference 
Ktrans, Kep and ve (DCE MRI) 38 pCR Differences for three parameters 
between pCR and non-pCR (p<0.05). 
ROC AUC for Ktrans 0.92 (0.84, 1.00); Kep 




Perfusion parameters (DCE 
MRI) 
30 dTRG Late slope differed between good and 
poor responders, AUC 0.90 
N Prospective (157) 
PImean (DCE MRI) 83 pCR NS Y Prospective (158) 







pCR Predictive model using cT, cN, 
skewness, entropy and max fractal 
dimension (FD) with AUC 0.77 +/- 0.07 







Tumour compactness (T2 
MRI) 
122 pCR HR 4.103 (1.801-9.346), p=0.001. Y Retrospective (71) 
T2 signal intensity and 
tumour volume (T2 MRI) 
48 pCR; 
dTRG 
NS - Prospective (160) 






pCR Logistic regression model using 
covariates cT, skewness and entropy. 
Model AUCs were 0.73 (internal) and 
0.75 (external). 
Y Retrospective (161) 
EMD for T3 invasion (T2 MRI) 111 pCR; 
dTRG 
EMD significantly higher in non-pCR (7.8 
± 3.2 mm) than pCR (6.1 ± 1.8 mm), 
p=0.033; NS for dTRG. 






Parameters assessed n Outcome Findings Multivariate 
analysis 
Study Design Reference 
EMD for T3 invasion (T2 MRI) 118 pCR Less T3 invasion associated with pCR 
[OR, 0.74 (0.62–0.90), p<0.002]. 
Likelihood of pCR decreased by 35% for 
every mm of EMD invasion.  
N Retrospective (163) 
ADC = apparent diffusion co-efficient; EMD = extramural depth of invasion; PI = perfusion index; Dapp = apparent diffusion parameter of Gaussian distribution; Kapp = apparent 
kurtosis coefficient; DCE = dynamic contrast enhanced; ve = extracellular extravascular space volume fraction; Ktrans = volume transfer constant; Kep = rate constant (Ktrans/ve). 
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MRI is an imaging modality with a large number of techniques possible, each with different 
uses. Diffusion weighted MRI allows mapping of water molecules as they move in biological 
tissues, and  has received the most attention of MRI techniques in attempts to predict 
response to nCRT. Of the eight studies assessing perfusion parameters none have provided 
strong evidence to support this modality as a predictor. 
Two studies found less extra-mural invasion of T3 tumours was associated with greater 
chance of pCR but these studies did not perform multivariate analysis (162, 163). The clinical 
utility of this is doubtful in the context of only modest predictive ability of clinical T stage 
overall; to sub-classify T3 into responders and non-responders seems unlikely to allow 
advancement in patient selection for radiotherapy.  
Dynamic contrast enhanced (DCE) MRI measures T1 changes in tissues over time after 
gadolinium contrast is administered intravenously and allows assessment of perfusion 
parameters. Martens et al found the late slope had an excellent AUC in their small 30 patient 
study (157) but this requires further investigation. 
Radiomics is a term used to describe the conversion of radiological images into data that can 
then be examined.  Cusumano et al used this approach and developed a model that was 
internally validated (159), but this approach still requires external validation. 
1.2.3.3.2 Positron Emission Tomography (PET) 
PET holds interest as a predictor because it is a type of functional imaging demonstrating 
metabolic activity which may be associated with treatment response. Although structural 
elements may contribute to response e.g. T and N stage, functional imaging usually aims to 
combine structural and functional information. Fluorodeoxyglucose (FDG) PET is based on 
the premise that tumours consume large amounts of glucose as a preferential energy 
substrate, even in the presence of normally functioning mitochondria, a phenomenon 
known as the Warburg Effect (164). FDG is the most common tracer and was used in all 
studies except Withofs et al (165). 
Numerous studies have explored PET, usually combined with CT, as a method to predict 
response. The results are presented in Table 1.14, and while there have been differences 
seen in parameters between good responders and poor responders, no study has resulted in 
a predictor with adequate utility for clinical use. 
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Table 1.14. PET parameters as predictors of pathological response to nCRT for rectal cancer 
Parameters assessed n Outcome Findings Multivariate 
analysis 
Study Design Reference 
SUV, MTV, TLG, 
textural analysis 
74 dTRG MTV calculated using SUVmean of liver associated with 
TRG; others NS 
Y Retrospective (36) 
SUVmax, MTV 35 dTRG NS - Retrospective (166)  
SUV 31 dTRG NS - Prospective (167) 
SUVmax, SUVmean, MTV 
and TLG 
103 pCR NS - Retrospective (168) 
SUVmax, MTV, TLG 81 pCR NS - Retrospective (169) 




MTV-pre lower in pCR group (9.87 vs. 14.62 cm3, p = 
0.045) 
N Prospective (76) 
SUVmax, MTV, TLG, 
others 
69 dTRG NS - Retrospective (170) 
SUVmax  80 TRG Median SUVmax at baseline higher for TRG 1 (minimal 
response) compared other TRG categories 
N Prospective (171) 
SUVmax 99 pCR NS Y Prospective (172) 
[18F]FPRGD2 SUVmax, 
SUVmean 
32 pCR; TRG [18F]FPRGD2 uptake higher in pCR; SUVmean moderately 
correlated with TRG (Spearman’s r= −0.41, p=0.019).  
N Prospective (165) 






This systematic review examines the last ten years of literature investigating predictors of 
pathological response to neoadjuvant chemoradiotherapy for rectal cancer. It provides a 
broad overview of a large topic, attempting to provide context and background for the large 
number of predictors identified and the different techniques employed in attempts to 
predict response. 
Of the large amount of literature examined, several predictors appear to have current 
clinical utility. Clinical predictors including advanced T and N stage, advanced tumour size 
and mucinous histology have moderate evidence to support their roles as predictors of poor 
pathological response. It is important to consider that the majority of these factors are also 
relative indications for neoadjuvant radiotherapy; although the response is less likely to be 
good, a good response is also of greater clinical importance. The only clinically useful 
biomarker available is CEA, and an elevated CEA has been found predictive of poor 
pathological response also. The role of advanced imaging characteristics is evolving, but 
currently there is not adequate evidence to support advanced imaging as a predictor in 
clinical practice. As individual predictors, none are strong enough to allow treatment 
decisions to be based on them currently.  
There are numerous limitations of a systematic review of this nature. The large amount of 
heterogeneity in the literature prevents quantitative assessment by meta-analysis, although 
this is possible for selected predictors. This review considers any pathological measure of 
regression, including pCR or a recognised TRG. This has the benefit of identifying a large 
number of additional predictors that have not been reported for pCR, but brings much more 
heterogeneity to the subject which makes interpretation difficult. There are multiple 
different TRG systems, and no attempt has been made to relate the specific TRG grading 
system used in each instance, although they have some common features and are 
dichotomised in a similar way to categorise patients as good responders or poor responders. 
Although not formally assessed, it is likely there is significant publication bias in the 
literature reviewed due to the presence of a large number weakly positive studies with low 
participant numbers. 
Study size is important when considering a pCR rate may be <20%, small studies will have 
very low numbers in a pCR group. This may often be the reason dichotomised TRG is used as 
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an outcome, although it provides different information to pCR. This review limited studies to 
those with >30 participants, but this could result in five patients or less with pCR, or 
approximately 15 with GR by dTRG. Many biomarker studies contained small numbers of 
patients meaning they were really pilot/exploratory studies. 
Several studies reported scoring systems using either clinical factors or biomarkers as 
predictors. Small numbers of participants was common and such results are rarely 
generalisable to other patient populations. 
The most clinically relevant predictors at the current time are clinical T and N stage, and CEA 
level. These predictors are pieces of routinely available clinical information with 
reproducibility between observers and no additional cost incurred. Expert radiologists are 
likely to be concordant when following appropriate reporting guidelines. These predictors 
have been assessed in the largest number of patients including up to three large 
retrospective studies with more than 18,000 participants each. Although these predictors 
offer some utility, this is limited and there is a clear need for better predictors to be 
identified in order to significantly inform treatment decisions. In the following three 
chapters an attempt is made to progress this field by investigating retrospective clinical 





2 Clinical Predictors of the Pathological Response to Neoadjuvant 
Chemoradiotherapy for Locally Advanced Rectal Cancer at 
Christchurch Hospital 
2.1 Introduction 
There is potential clinical benefit in predicting the response to chemoradiotherapy for 
patients with rectal cancer. This includes a recommendation of chemoradiotherapy if a good 
response is likely, either as neoadjuvant treatment or planned non-operative management, 
or a recommendation to proceed straight to surgery if a poor response is likely. The current 
standard of care is that patients with locally advanced rectal cancer (LARC) will be offered 
neoadjuvant radiotherapy if there are not contraindications. Therefore if radiotherapy is 
indicated they are likely to receive it unless there was a reliable predictor of poor response 
and up to 40% of patients will experience minimal-poor response (26). Radiotherapy for 
rectal cancer carries significant morbidity (25, 173), and in the New Zealand setting often 
requires extended periods of geographical and social isolation for patients and families from 
rural regions who need to attend a radiotherapy centre hundreds of kilometres away. While 
pathological complete response (pCR) is a robust outcome measure and has been a major 
focus of the literature, this is not the only measure of clinical utility. Predicting a good or 
poor response may also be useful. 
Clinicopathological predictors are important as they include information routinely available 
in the clinical environment. The literature regarding clinical predictors of response to 
neoadjuvant chemoradiotherapy (nCRT) for rectal cancer has been extensively reviewed in 
Chapter 1. In summary, factors associated with pCR include smaller tumour size, non-
circumferential tumours, lower clinical T and N stage, well-differentiated, non-mucinous and 
signet ring histological sub-types and lower pre-treatment carcinoembryonic antigen (CEA) 
level (37, 48, 51, 53, 63, 68, 174). Significant variation has been found globally for the pCR 
rate to nCRT for rectal cancer. A retrospective study of 297 patients from Auckland, New 
Zealand examining clinical predictors found a pCR rate of approximately 10% and included 
historical data now up to 16 years old.  Christchurch Hospital is a major tertiary referral 
centre treating among the greatest volume of rectal cancer patients of any centre nationally, 
but the pCR rate and predictors of pCR have not previously been investigated. 
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Clinical scoring tools are common and some have become established in routine medical and 
surgical practice (175-177). Maximal utilisation of clinicopathological information might be 
achieved through development of a clinical risk scoring tool to predict the response to nCRT 
for rectal cancer. Previous attempts to create a predictive model have been of limited 
predictive ability, are mathematically complex and do not allow easy use in the clinical 
setting (48, 51), or are from an era before high-quality total mesorectal excision (TME) was 
routinely performed and did not report on pCR or TRG as an outcome measure (178). 
The primary aim of this study was to identify pre-treatment clinicopathological factors that 
correlate with tumour regression grade (TRG) and/or pCR after nCRT followed by TME for 
rectal cancer. The secondary aim was to develop a simple clinical scoring system to predict 
response to radiotherapy for rectal cancer. 
2.2 Method 
This was a retrospective observational study performed at Christchurch Hospital, a tertiary 
referral hospital in New Zealand. Ethics approval was obtained from the Southern Health and 
Disability Ethics Committee (ref: 18/STH/150); individual patient consent was not required. 
Patients with a histological diagnosis of cancer from a rectal specimen were identified from 
the Christchurch Hospital Department of Pathology database from August 1 2013 to August 
1 2018. The electronic clinical record of all patients identified was examined. The inclusion 
criteria was adult patients (>18 years of age) with histologically confirmed rectal 
adenocarcinoma, treated with neoadjuvant long-course radiotherapy and concurrent 
fluoropyrimidine-based chemotherapy followed by TME. Patients with distant metastatic 
disease (stage IV disease) diagnosed prior to TME were excluded. 
Clinicopathological data was collected from the electronic clinical records including pre-
treatment patient and disease factors, treatment and post-treatment variables including the 
presence of a pCR and the American Joint Committee on Cancer (AJCC) TRG (Table 2.1). All 
data required has been kept electronically in Christchurch Hospital since prior to the study 
period. The AJCC TRG is routinely reported for all rectal cancer treated with neoadjuvant 
radiotherapy in Christchurch Hospital; multiple pathologists report rectal cancer specimens. 
Data was recorded in a secure Microsoft Excel spreadsheet and analysed using IBM SPSS 25. 
TRG was dichotomised to categorise patients into two groups, good responders (TRG 0-1) or 
minimal-poor responders (TRG 2-3). Analysis was performed for the outcome variables of 
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pCR and good response (TRG 0-1). Univariate analysis was performed using the χ2 test or 
Fisher’s exact test for categorical variables, the Mann-Whitney U test for nonparametric 
continuous variables and independent samples t test for parametric continuous variables. 
Variables which were significant or near significant (p<0.15) on univariate analysis were 
entered into a binary logistic regression model. An attempt to create a clinical scoring tool 
using a binary score (0 or 1) for significant predictors was attempted, with predictive ability 
assessed using the area under the curve (AUC) of the receiver operating curve (ROC). 
Table 2.1. AJCC tumour regression grading system (reproduced from reference (179)) 
Description TRG 
No viable cancer cells (complete response) 0 
Single cells or small groups of cancer cells (moderate response) 1 
Residual cancer outgrown by fibrosis (minimal response) 2 
Minimal or no tumour kill; extensive residual cancer (poor response) 3 
 
Neoadjuvant treatment for rectal cancer at Christchurch Hospital routinely includes 45 Gray 
whole pelvis irradiation and a 5.40 Gray boost to the tumour in 28 fractions over five and a 
half weeks, with concurrent capecitabine or 5-fluorouracil (5-FU) dose adjusted as clinically 
indicated.  
2.3 Results 
Over the five years of the study 470 patients were seen with rectal cancer, of which 51 
patients received pre-operative short-course radiotherapy and 195 patients received long-
course chemoradiotherapy. Thirty-one (31/195) long-course chemoradiotherapy patients 
were excluded because they had metastatic disease at presentation or did not undergo TME, 
leaving a study population of 164 patients.  117/164 (71.3%) were male and the median age 
of all patients was 66 years (range 31-85 years) (Table 2.2). pCR and TRG rates are shown in 
Table 2.3. The pCR rate was 14.6% overall, although there was an apparent increase over 
time with a pCR rate of 19.4% for the last three years of the study. TRG was available for 




Table 2.2. Demographics and clinical stage of study population 





















































Table 2.3. AJCC tumour regression grade (TRG) and pCR rates for all patients 
















pCR 24* 14.6 
*pCR rate not equal to TRG 0 because TRG does not consider LN involvement. 
 
Table 2.4 compares pre-treatment clinicopathological variables by pCR status and 
dichotomised TRG. On univariate analysis clinical nodal stage (cN) was lower in the pCR 
group than non-pCR group, and tumour length on MRI was shorter. Good responders had an 
older median age by four years (68 vs. 64 years), lower clinical tumour stage (cT) and shorter 
tumour length on MRI. Maori patients were significantly less likely to get a good response; 
although only six Maori patients were included none of these patients achieved a good 
response. This result was not explained by advanced clinical stage at diagnosis. There was 
also a significant difference for tumour position with good responders more likely to have 
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Table 2.4. Univariate analysis of pre-treatment clinicopathological factors grouped by pathological complete response and good response (TRG 0-1) 













Age (years) median 69.00 65.00 0.085  68.00 64.00 0.048 66.00 
Gender   0.300    0.692  
Male 15 (12.8%) 102 (87.2%)  117 51 (44.7%) 63 (55.3%)  114 
Female 9 (19.1%) 38 (80.9%)  47 19 (41.3%) 27 (58.7%)  46 
Ethnicity#         
NZ European 21 (14.6%) 123 (85.4%) 0.961 144 61 (43.3%) 80 (56.7%) 0.735 141 
Maori  0 (0.0%) 6 (100%) 0.301 6 0 (0.0%) 6 (100.0%) 0.028 6 
Asian  2 (28.6%) 5 (71.4%) 0.286 7 3 (50.0%) 3 (50.0%) 0.753 6 
Other European 2 (8.7%) 21 (91.3% 0.385 23 8 (38.1%) 13 (61.9%) 0.575 21 
Other 5 (21.7%) 18 (78.3%) 0.298 23 11 (47.8%) 12 (52.2%) 0.670 23 
BMI mean 26.7 28.2 0.257  27.0 28.7 0.090  
Diabetes (on medication)         
Yes 1 (5.9%) 16 (94.1%) 0.295 17 4 (26.7%) 11 (73.3%) 0.156 15 
No 22 (15.3%) 122 (84.7%)  144 65 (45.8%) 77 (54.2%)  142 
Current smoker         
Yes 2 (10%) 18 (90%) 0.517 20 7 (35.0%) 13 (65.0%) 0.370 20 
No 22 (15.5%) 120 (84.5%)  142 63 (45.7%) 75 (54.3%)  138 
Clinical T stage   0.106    0.040  
T2 6 (22.2%) 21 (77.8%)  27 14 (53.8%) 12 (46.2%)  26 
T3 16 (16.5%) 81 (83.5%)  97 46 (51.0%) 50 (49.0%)  96 
T4 2 (5.0%) 38 (95.0%)  40 10 (26.3%) 28 (73.7%)  38 
Clinical N stage   0.022    0.089  
N0 9 (28.1%) 23 (71.9%)  32 19 (61.3%) 12 (38.7%)  31 
N1 10 (15.6%) 54 (84.4%)  64 25 (40.3%) 37(59.7%)  62 
N2 5 (7.3%) 63 (92.7%)  68 26 (38.8%) 41 (61.2%)  67 
cN positivity (cN1 or cN2) 15 (11.4%) 117 (88.6%) 0.018 132 51 (39.5%) 78 (60.5%) 0.018 129 
Distance from anorectal margin on MRI 
(mm), median (range) 
27.50 (0-
150) 
31.00 (0-132) 0.988 157 34.50 (0-150) 30.00 (0-132) 0.337 153 
Differentiation   0.508    0.893  
Well 0 (0.0%) 3 (100.0%)  3 1 (33.3%) 2 (66.7%)  3 
Moderate 14 (13.2%) 92 (86.8%)  106 46 (45.1%) 56 (54.9%)  102 
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Poor 0 (0.0%) 6 (100.0%)  6 3 (50.0%) 3 (50.0%)  6 
Mucinous histology 2 (28.6%) 5 (71.4%) 0.313 7 5 (71.4%) 2 (28.6%) 0.137 7 
Signet ring histology 0 (0.00%) 3 (100.0%) 0.459 3 2 (66.7%) 1 (33.3%) 0.428 3 
Position   0.521    0.036  
Anterior 7 (21.2%) 26 (78.8%)  33 22 (68.8%) 10 (31.3%)  32 
Posterior 6 (18.2%) 27 (81.8%)  33 14 (42.4%) 19 (57.6%)  33 
Lateral 3 (15.8%) 16 (84.2%)  19 9 (50.0%) 9 (50.0%)  18 
Circumferential 7 (12.1%) 51 (87.9%)  58 21 (36.8%)  36 (63.2%)  57 
Not circ, NOS 0 (0.00%) 9 (100.0%)  9 2 (25.0%) 6 (75.0%)  8 
Macroscopic ulceration 14 (33.3%) 42 (66.7%) 0.436 56 29 (52.7%) 26 (47.3%) 0.637 55 
Tumour length on MRI (cm), mean 4.04 5.09 0.011 161 13.9 18.5 0.003 157 
Tumour length on MRI ≥3cm 20 (13.2%) 131 (86.8%) 0.043 151 61 (41.5%) 86(58.5%) 0.020 147 
Tumour length on MRI ≥5cm 7 (10.1%) 62 (89.9%) 0.105 69 22 (33.3%) 44 (66.7%) 0.017 66 
Tumour fixity 2 (13.3%) 13 (86.7%) 0.502 15/28 had 
tumour fixity 
6 (42.9%) 8 (57.1%) 0.568 14/27 had 
tumour fixity 
Haemoglobin, mean 132.17 132.73 0.838  135.46 130.68 0.110  
Anaemic  8 (16.3%) 41 (83.7%) 0.672 49 19 (39.6%) 29 (60.4%) 0.509 48 
Not anaemic 15 (13.8%) 94 (86.2%)  109 48 (45.3%) 58 (54.7%)  106 
Neutrophil, mean 4.47 5.04 0.226 158 4.7742 5.0644 0.397 154 
Lymphocyte, mean 2.07 2.01 0.719 158 2.0509 2.0069 0.715 154 









CEA <5 18 (18.4%) 80 (81.6%) 0.043 98 45 (46.9%) 51 (53.1%) 0.139 96 




When participants with a poor response (TRG 3) were compared with the remaining 136 
patients, there was no significant difference in any of the pre-treatment variables examined. 
Although histological differentiation was different between the groups (χ2 7.380, 2 d.f., 
p=0.025) the chi-square test was invalid due to low expected cell counts. Six patients had 
poorly differentiated tumours identified on pre-treatment biopsy and 2/6 (33.3%) had a TRG 
3 compared with 15% of all patients. 
2.3.1 Binary Logistic Regression  
Binary logistic regression was performed using a stepwise backwards elimination approach 
for the outcomes of pCR and good response. For pCR the model was initiated with age, cT, 
cN and tumour length on MRI and CEA as predictors but individual factors only achieved 
significance when the model was reduced to include only length on MRI, cN stage and age. 
The χ2 was 14.779 with 3 d.f. and p=0.002.  The Hosmer and Lemeshow test did not 
demonstrate poor fit (p=0.632). The R2 statistic was 0.154. Greater length of tumour on MRI 
and cN2 stage were independent predictors of non-pCR when adjusting for each other and 
age. cN0 did not reach statistical significance although there was a trend towards increased 
chance of pCR [OR 2.338 (0.849-6.436), p=0.10]. 
In the final regression model for predictors of good response, anterior position, 
circumferential tumours, higher BMI and lower haemoglobin were independent predictors 
for not achieving good response after adjusting for age, length on MRI and mucinous 
features on pre-treatment biopsy (Table 2.5). The χ2 was 31.680, 11 d.f. and p=0.001. The 
Hosmer and Lemeshow test did not demonstrate poor fit (p=0.457). The R2 statistic was 
0.269. 
Table 2.5. Independent predictors of pathological complete response and good response (TRG 0-1) on 
binary logistic regression 
Predictors of pCR OR (95% CI) p value 
Length on MRI (cm) 0.676 (0.462-0.990) 0.044 
cN2 stage 0.283 (0.080-0.997) 0.050 
Predictors of good response (TRG 0-1) OR (95% CI) p value 
BMI 0.888(0.815-0.968) 0.007 
Anterior position 0.255 (0.068-0.960) 0.043 
Circumferential tumours 0.329 (0.108-0.995) 0.049 




2.3.2 Scoring System 
An attempt to develop a clinical risk score for pCR was made by assigning a score of 1 for the 
events length <5cm, CEA greater than 5 ng/mL and cN0 (all significant on univariate 
analysis). Scores were generated for 88 participants who had data for all variables, and the 
scores were 1 (n=16), 2 (n=58) and 3 (n=14). No score significantly improved the AUC of the 
ROC above 0.5.  
Similarly, an attempt to develop a clinical risk score for good response was made by 
assigning a score of 1 for the events T2-3, N0, anterior tumours and length <5cm (all 
significant on univariate analysis). This yielded a score for 75 patients (score 0-1=0, score 
2=46, score 3=21, score 4=8) who had data for all variables. No score significantly improved 
the AUC of the ROC above 0.5. 
2.3.3 Post-Treatment Variables 
Table 2.6 outlines the operative and pathological outcomes for the study population. There 
was an R0 resection rate of 90.1% and grade 3 TME in 68.8% of patients. Sphincter-
preserving surgery (with or without anastomosis), as opposed to abdominoperineal excision, 
was performed in 65% of cases. On univariate analysis tumours with a higher TRG (poorer 
response) were significantly more likely to have lymphovascular invasion (p=0.027) and 
perineural invasion (p=0.007) in the resection specimen (Table 2.7). There was no difference 
in TRG for an infiltrative tumour margin compared with a pushing margin, when tumour-





Table 2.6. Operative and pathological outcomes for all patients 
 Frequency % 

























Mucinous histology 11/141 7.8 
Signet ring histology 3/140 2.1 
Lymphovascular invasion 22/139 15.8 































Sphincter-preserving surgery 104/160 65.0 
 
Table 2.7. Pathological features of resection specimens associated with tumour regression grade on 
univariate analysis. 
AJCC TRG 1 2 3 p value 
Lymphovascular 
invasion 
1/44 (2.3%) 15/66 (22.7%) 5/24 (20.8%) (p=0.027) 
Perineural 
invasion 





This study describes clinicopathological factors and their association with pathological 
response, assessed by either pCR or TRG, in 164 patients with stage 1-3 rectal cancer treated 
with nCRT and TME over a 5 year period at Christchurch Hospital.  
The overall pCR rate of 14.6% and pCR rate of almost 20% in the last three years is 
comparable with published rates worldwide (26). The pCR rate in this study is slightly higher 
than the 10% previously reported in a New Zealand cohort (68), which may be the most 
comparable published dataset. Significant regional variation in indications for long and short 
course radiotherapy are known to exist in New Zealand and may contribute to this 
difference.  Another explanation is the long time period of the previous study (68) which 
extended back to 2002, and numerous treatment factors may have varied over this time. 
For pCR as an outcome measure, this study was largely concordant with the published 
literature. Clinical N stage was an independent predictor, although a statistically significant 
difference was only identified for cN2 patients on logistic regression. Decreasing tumour size 
was associated with pCR in the current study and has been shown by many others (see 
chapter 1). The literature shows no clear association with distance from the anus and this 
study found no association with distance from anorectal junction on MRI. Although distance 
from anal verge on rigid sigmoidoscopy is the gold standard, this was rarely available from 
the clinical records hence the decision to use the MRI measurement which is included in 
synoptic reporting. Clinical T stage was only associated with good responders on univariate 
analysis in this study, and the literature demonstrates cT stage as an independent predictor 
of pCR only in two very large studies (>18,000 each) suggesting a real but small effect 
unlikely to be seen in a study this size. Tumour mobility data was very poor in our study with 
only 28 patients having data available meaning the value of this is minimal. This study had 
low numbers of patients with mucinous (n=7) and signet ring (n=3) histology, concordant 
with known percentage of cases of rectal cancer, and it is likely these numbers were too 
small to identify any association present.  Anterior tumour position was found to be an 
independent predictor of good response (but not pCR) which is a new finding and has not 
been reported elsewhere, and non-circumferentiality was an independent predictor of good 
response, concordant with some small retrospective studies reviewed in chapter 1. 
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It was not possible to identify predictors of poor response (TRG 3), although this remains an 
important question because there is a relative paucity of published data on this and the 
clinical utility may be underappreciated. As neoadjuvant radiotherapy is standard of care for 
LARC, an accurate predictor of poor response could spare a significant proportion of patients 
from radiotherapy, with major clinical and socioeconomic benefits. 
In this study dichotomised TRG was used as an outcome measure and different factors 
predictive of good response by TRG were identified compared with an outcome of pCR. 
There are several potential reasons for this. Firstly, a good response is different from a pCR 
in that not only can small volume disease may remain in the bowel wall, but lymph nodes 
may also be involved. Expectedly, nodal status is not a predictor of TRG 0 as nodal 
involvement does not feature in the AJCC TRG. In addition, 43.7% patients were good 
responders compared with 15% pCR, and the chance of achieving statistical significance was 
greater with the sample size included.  
There have been numerous TRG systems proposed; the AJCC TRG has been in use for over 
five years at Christchurch Hospital and is routinely available in pathology reports. The 
Dworak (or a modified version) has been proposed as superior (28) but it was not possible to 
assess Dworak TRG in this study because it was rarely reported. Research to elucidate the 
optimal TRG remains important, and would allow some standardisation of research 
outcomes in the field. 
The post-treatment pathological features must be viewed with some caution. Histological 
differentiation of the resection specimen has not been reported as neoadjuvant treatment 
can limit interpretability of this, and indeed significant treatment effects can make 
pathological assessment challenging, including the presence of mucin pools in the absence 
of mucinous histological sub-type. Lymphovascular and perineural invasion were present 
more often in those with higher TRG (poorer response) and although this data is not a pre-
treatment predictor, LVI and PNI was not identified in any of the diagnostic biopsies 
therefore no conclusions can be made regarding their presence in pre-treatment tissue. 
Diagnostic biopsies may be too superficial to identify lymphatic vessels; although lymphatic 
vessels have been demonstrated in the lamina propria of neoplastic colonic epithelium they 
don’t appear to be present in normal colonic epithelium (180) so the extent of neoplasia will 
play a role in determining their presence. However, if these features are seen on diagnostic 
64 
 
biopsy this may indicate potential resistance to treatment, and care to identify these 
features on pathological assessment of diagnostic biopsies may be valuable. 
Clinical scoring systems are well-established in medicine and surgery, with wide uptake of 
scoring systems for predicting severity of pancreatitis (177), pneumonia (175), and mortality 
associated with sequential organ failure in the intensive care unit (176). For a scoring system 
to be generalisable it should usually not be mathematically complex, especially if developed 
on a relatively small study population. Complexity is also likely to decrease uptake in clinical 
practice. Furthermore, for a scoring system to be useful it must provide additional 
information over what is immediately apparent on clinical assessment.  
Although previous scoring systems have been created to predict response to nCRT for rectal 
cancer they have not achieved uptake due to a combination of these factors. Joye et al 
identified a number of clinical variables associated with pCR on logistic regression, and used 
a ROC to assess the discriminative ability of the prediction models (48). Although they 
achieved statistical significance the AUC for the ROC was 0.609 proving it an inadequate tool 
for prediction.  Huh et al stratified patients into four risk groups based on clinical predictors 
identified on logistic regression (51). A group categorised as ‘low risk’ was most predictive of 
response to therapy but the predictive ability remained inadequate for clinical use with a 
sensitivity of 64.1%, specificity of 73.7% and AUC of ROC 0.706. 
A major difficulty in creating a scoring system in this setting is a relatively small number of 
independent predictors, and the fact the effect size of each is not great. A clinical scoring 
system is unlikely to be of utility in predicting the response to nCRT and other avenues 





3 The Role of Mitochondria, Oxidative Stress and Antioxidants 
Including Peroxiredoxins in Radiation Sensitivity for Rectal 
Cancer: Narrative Literature Review 
Previously published and co-authored work. 
Fischer J, Eglinton TW, Frizelle FA, Hampton MB. Peroxiredoxins in Colorectal Cancer: 
Predictive Biomarkers of Radiation Response and Therapeutic Targets to Increase Radiation 
Sensitivity? Antioxidants (Basel). 2018 Oct 5;7(10). pii: E136. doi: 10.3390/antiox7100136. 
3.1 Introduction 
Radiotherapy is a vital tool in cancer therapy, and is used in the treatment of a wide range of 
malignancies including gastrointestinal, genitourinary, head and neck, central nervous 
system and skin cancer. Radiotherapy may be used as a sole treatment, or in a neoadjuvant 
or adjuvant setting when combined with surgery. Radiotherapy is used commonly for rectal 
cancer due to proven benefit in reducing the rate of local recurrence, but the response is 
highly variable, with approximately 20% of patients experiencing a pathological complete 
response (pCR), and up to 40% demonstrating minimal regression or even tumour 
progression (26). The ability to predict the response to radiotherapy could crucially inform 
the decision when considering radiotherapy for rectal cancer. Patients likely to experience a 
poor response may be best to proceed straight to surgery thereby avoiding treatment delay 
and morbidity of radiotherapy; those predicted to have a good response would be best to 
receive radiotherapy and may even be considered for non-operative management if a 
complete clinical response is achieved, thereby avoiding the significant risk of mortality and 
morbidity with rectal cancer surgery.  
Ionising radiation (IR) kills cells by directly damage to biomolecules and the generation of 
reactive oxygen species during the radiolysis of water (181). This immediate damage is not 
the only challenge faced by irradiated cells. Redox homeostasis can be disrupted for several 
weeks, compromising the viability of progeny and bystander cells. While the exact 
mechanisms of redox disruption are unclear, irreparable damage to nuclear and 
mitochondrial DNA is thought to increase cellular oxidant production and/or compromise 
antioxidant defences, ultimately leading to sustained oxidative stress and cell death (182). 
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Cells irradiated in the absence of oxygen are considerably more resistant to IR (183) 
confirming the importance of oxidative stress. Increased expression of manganese 
superoxide dismutase (MnSOD) and mitochondria-targeted catalase have both been shown 
to protect against IR-induced cell death (184-187) and chronic glutathione depletion 
increases radiosensitivity (188). In this review we focus on the peroxiredoxin family of 
antioxidant proteins (Figure 3.1). These thiol-dependent peroxidases are abundant in 
mammalian cells and effectively reduce hydroperoxides (189, 190). Humans have six 
different peroxiredoxins (Prx1-6) with varying cellular locations: peroxiredoxin 1, 2, and 6 are 
present in the cytoplasm and nucleus; peroxiredoxin 3 present solely in mitochondria; 
peroxiredoxin 4 present solely in the endoplasmic reticulum and peroxiredoxin 5 in the 
cytoplasm, mitochondria, and peroxisomes (191). The catalytic activity of the peroxiredoxins 
is dependent on an active cysteine (Cys) site that is oxidized to a sulfenic acid by 
hydroperoxides. For Prxs 1-4 a resolving Cys on the second subunit of the homodimer forms 
an intermolecular disulfide bond. Conversion back to the reduced state requires thioredoxin 
or glutaredoxin activity, and in cells under increased oxidative stress, the oxidized forms 
accumulate. In various systems we have observed that the redox status of endogenous 
peroxiredoxins can act as a sensitive biomarker of redox homeostasis (192, 193).  
All peroxiredoxins have been shown to have altered expression in human cancer (191). In 
this chapter we review the role peroxiredoxins play in radiation sensitivity for colorectal 
cancer (CRC), their potential as predictive biomarkers of radiation sensitivity, and to consider 
the therapeutic implications.  
3.2 Radiation Therapy for Colorectal Cancer 
Approximately one third of cases of CRC are of rectal origin which affects about one in 60 
adults in the Western world (194). While colon and rectal tissue is histologically similar, the 
clinical behaviour and management of colon and rectal cancer differs significantly and they 
have also demonstrated different outcomes to adjuvant chemotherapy in a clinical setting 
(195). Colon cancer is usually treated with bowel resection with or without adjuvant 
chemotherapy and radiotherapy is rarely used, in contrast with rectal cancer treatment 
where radiotherapy is common. Historically, local recurrence has been a significant issue 
following surgery for rectal cancer. The development of improved surgical technique with 
total mesorectal excision and the use of preoperative radiation therapy has significantly 
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reduced local recurrence rates (7, 8). In addition, the anatomical arrangement of the rectum 
in the pelvis away from small bowel allows tumour targeting with less radiation delivery to 
the vulnerable small bowel. The addition of fluoropyrimidine-based chemotherapy such as 5-
fluorouracil to a radiotherapy regimen improves effectiveness of this treatment (13). The 
highly variable response rate of rectal cancer to radiotherapy is however a major challenge 
in the management of patients with the disease. 
There is a significant shift occurring in the approach to rectal cancer treatment. In selected 
cases, organ preservation (i.e. omitting resection of the rectum) is offered after neoadjuvant 
chemoradiotherapy if a complete clinical response (determined by clinical and endoscopic 
examination, and radiological re-assessment with MRI) is achieved.  The omission of surgery 
has major implications in that the chance for early cure with surgery may be missed, and 
death from rectal cancer progression may result. The benefits of omitting surgery are a 
reduction in morbidity and mortality resulting from surgery. For rectal cancer surgery these 
risks are significant, with an in-hospital mortality rate of 1-2%, over 30% of patients having 
significant post-operative complications and 20-30% of patients requiring a permanent 
stoma (4). Similarly, radiotherapy also carries significant morbidity (25, 173), and if a poor 
response could be reliably predicted then the omission of radiotherapy would be in the 
patient’s best interests and they should proceed directly to surgical resection. While there 
has been a large volume of research investigating predictors of pCR which can be classified 
as clinicopathological, radiological and biomarkers, but no robust predictors have been 
identified (26). 
3.3 Redox Homeostasis, Mitochondria and Radiosensitivity 
Irradiation of cells causes direct damage to biomolecules and the radiolysis of water. Within 
fractions of a second, a series of reactive radical species are generated, and in the presence 
of oxygen this results primarily in superoxide, hydrogen peroxide and hydroxyl radical 
formation (181), and also reactive nitrogen species (181). As well as this early acute burst a 
persistent increase in oxidative stress for hours to days after radiation exposure has been 
reported (181). This sustained stress, if not lethal, is passed to daughter cells, implicating 
alterations to nuclear or mitochondrial genomes (182). 
Mitochondria are prominent sources of reactive oxygen species and targets of oxidative 
stress, and are hypothesized to be a major target of injury by radiation. In 1965 Goldfeder 
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first hypothesized mitochondria play a role in radiosensitivity, based on the fact that cells 
with large numbers of mitochondria still function if irradiation compromises a substantial 
proportion (196). Mitochondrial DNA appears more susceptible to damage by IR and 
chemically-induced oxidative stress (182). This DNA codes the subunits of the electron 
transport chain (ETC) (197-200) which is an important site of superoxide production (201). 
Multiple experimental studies have shown that IR directly impacts ETC complexes and ATP 
synthesis, disrupting oxidative phosphorylation (182).   
Leach et al showed that when osteosarcoma cells lacking mitochondrial DNA were irradiated 
there was no increase in secondary redox disruption, supporting a central role for 
mitochondria (202). Leach et al also found the calcium binding protein calbindin limited 
redox changes, suggesting that calcium played a role in the secondary response (202). 
Signalling between mitochondria and the nucleus may also be affected by IR; elevation in a 
marker of nuclear DNA damage was shown five minutes after nuclear targeting with 
microscopic irradiation, compared to three hours after cytoplasmic irradiation (202). 
Furthermore, the bystander effect was not observed when cells deficient in mitochondrial 
DNA were used suggesting mitochondrial function was an essential element of intercellular 
signalling. Richardson and Harper found that uncoupling the ETC lowered oxidant production 
and decreased radiosensitivity especially for hypoxic tumours (203). They demonstrated that 
damage to oxygenated tissue is related to mitochondrial oxygen consumption and the 
production of oxidants, and argued the primary radiation targets in oxygenated tissues are 
mitochondria that in turn target nuclear DNA. 
Cellular antioxidant systems are responsible for maintaining redox homeostasis and protect 
against the effects of oxidative stress, including DNA damage (204). As such, overexpression 
of these endogenous antioxidants can protect cells from radiation-induced injury. This effect 
was most significant for MnSOD, slight for glutathione peroxidase, while copper-zinc 
superoxide dismutase (Cu,Zn-SOD) appeared to make no difference (205-207). The fact that 
MnSOD resides in mitochondria while Cu,Zn-SOD is in the cytosol is consistent with 
mitochondrial damage playing a key role in radiation-induced injury. 
The role of dietary antioxidants in cancer therapy remains unclear (208). In contrast to 
cellular enzymes, it is difficult for small molecule oxidant scavengers to reach sufficient 
concentrations at intracellular sites to have significant impact. Antioxidant supplementation 
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has been reported to reduce side effects from chemotherapy (209), but this could 
potentially result in decreased treatment efficacy by reducing that oxidative damage that 
triggers cancer cell death. For example, the DNA-damaging ability of phenolic 
phytochemicals was shown to be inhibited by ascorbate and N-acetylcysteine in colon cancer 
cells (210) suggesting that antioxidants can modulate the response to DNA-damaging agents. 
There is currently no defined role for antioxidant supplementation in colorectal cancer 
patients. 
Differences in radiosensitivity have been found in cells of variable peroxiredoxin expression, 
and a protective effect against radiation has been found with increased Prx1, Prx2 and Prx4 
expression (211). Peroxiredoxins were proposed as a novel target for radiotherapy by Zhang 
et al (211), on the basis of expression induction by IR in a wide range of cell lines, including 
human HT29 colon cancer cells, as well as well as tissue including colorectal and non-
colorectal tumours (212-217), and an association between expression status and 
radiosensitivity of tumour cells including decreased radiosensitivity after knockdown of 
peroxiredoxins (217, 218). 
 
Figure 3.1. Overview of disrupted redox homeostasis and peroxiredoxin activity following exposure of 
cells to ionising radiation. 
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3.4 Peroxiredoxins and Colorectal Cancer 
There have been several studies examining peroxiredoxin expression in CRC (Table 3.1); with 
expression of all six peroxiredoxins reported to be increased (219). We review these studies, 
with particular focus on radiosensitivity for each peroxiredoxin.  












PRDX1   expression   
 radiosensitivity  
Yes   expression   
 response 
(220) 
PRDX2   expression   
 radiosensitivity  
Yes - (221-226) 
PRDX3  - - - (227) 
PRDX4  /  - Yes Yes  (219, 228, 
229) 
PRDX5  - - - (230) 
PRDX6  - - - (219) 
Legend:  = increased,  = decreased,  = association between expression and radiosensitivity or tumour 
response. 
3.4.1 Peroxiredoxin 1 
Prx1 expression is increased in CRC and has been suggested as a prognostic and predictive 
biomarker for rectal cancer on the basis of both in vitro and in vivo studies conducted by 
Chen et al (220). Prx1 expression as evaluated by immunohistochemistry (IHC) was 
significantly associated with a poor pathological response rate for 120 human subjects with 
rectal cancer treated with radiotherapy, with a response rate of 43.6% when there was 
negative staining and 20% when there was positive staining; this effect was accentuated 
when p53 staining was negative. Prx1 suppression by a Prx1 silencing vector increased 
radiosensitivity of HT-29 and HCT-116 colon cancer cell lines and inhibited tumour growth in 
a mouse model. Prx1 expression was also a significant predictor of disease free survival (DFS) 
in the group of patients who were p53 negative. The author’s conclusion that Prx1 
expression was associated with both poorer response to treatment and poorer prognosis 
appears justified but little work has been done to further investigate this.  
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3.4.2 Peroxiredoxin 2 
Peng et al demonstrated that both Prx2 mRNA and protein content was higher in CRC cell 
lines than normal colonic epithelial cells, and Prx2 expression was significantly upregulated 
in human CRC tissue compared with adjacent non-cancerous tissue (221). They also assessed 
clinicopathological correlation and identified an association between increased Prx2 
expression and poor histological differentiation, advanced local invasion, lymph node 
metastases and advanced tumour node metastasis stage, as well as shorter DFS, suggesting 
it may have a useful role as a prognostic marker for CRC (221).  In support of Prx2 expression 
as a stimulator of cancer progression, when a tumour knockdown of Prx2 was performed in 
a mouse model it was found to inhibit CRC cell growth, and when Prx2 silencing was 
performed in both a polyposis mouse model and human CRC cell lines, mouse polyposis was 
decreased by a reduction in beta-catenin as an end-point, and beta-catenin levels are 
reduced in the cells in which Prx2 is silenced (224). This suggests a mechanism of action 
involving the canonical Wnt signalling pathway. Although this is one of many molecular 
pathways in CRC development, the canonical Wnt pathway is disrupted in familial 
adenomatous polyposis due to germline mutations of the adenomatous polyposis coli gene, 
and commonly disrupted in sporadic CRC development. This raises the exciting possibility of 
therapeutic agents to limit polyposis progression in patients with familial adenomatous 
polyposis, as well as to modify risk of sporadic CRC. Lu et al also found that Prx2 was 
upregulated in CRC, and contributed to CRC cell survival by protecting cells from oxidative 
stress (222). 
In contrast to the above findings, an earlier study by Ji et al (225) examined mRNA and 
protein expression of Prx2 in CRC tissue of 137 patients, and found lower Prx2 expression 
was associated with poor differentiation, advanced cancer stage and poorer survival. They 
also looked for a correlation between serum Prx2 and OS or DFS and found none (225). 
There is no clear explanation of the difference between this study and that of Peng et al 
(221). 
Silencing of Prx2 expression has been shown to sensitize colon cancer cell lines to 5-
fluoruracil by facilitating cell death and apoptosis (226), and also to sensitize colon cancer 
cells to IR (217). Despite promising work with cell lines and xenograft models, there has been 
no investigation of Prx2 as a biomarker for pathological response to radiotherapy for rectal 
cancer in human subjects in vivo. 
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3.4.3 Peroxiredoxin 3 
Prx3 is the only mammalian peroxiredoxin that is present exclusively in mitochondria (231). 
Song et al collected tumour tissue from eight patients with colon cancer and investigated 
Prx3 expression using immunofluorescent and quantitative techniques (227). They found 
increased expression in colon cancer stem cells compared with normal colorectal tissue stem 
cells, and that cell death was not increased with escalating 5-fluoruracil dosing in colon 
cancer stem cells, showing some resistance to chemotherapeutic action. This suggests a cell 
survival advantage associated with Prx3 expression. The effect of Prx3 expression on 
radiosensitivity in CRC has not been examined, despite the importance of mitochondria in 
the response to IR. 
3.4.4 Peroxiredoxin 4 
The endoplasmic reticulum protein Prx4 has also been linked to CRC; Prx4 expression was 
higher in CRC tissue than normal colorectal tissue assessed with IHC and qPCR techniques, 
and increased Prx4 expression also correlated with negative clinical factors including depth 
of invasion and stage (228). In contrast, a small study that looked at peroxiredoxins in eight 
patients with CRC found Prx4 trending towards a lower positivity rate in CRC tumour tissue 
than normal controls and had no association with clinical stage or lymph node metastases 
(219). Prx4 expression by western blotting was slightly higher in normal control tissue than 
CRC tissue. Both these studies included small numbers of samples and statistical significance 
for positivity was not achieved in the second study, so this inconsistency may be a reflection 
of inadequate sample size. 
An exploratory study investigating novel markers predicting pathological response to 
chemoradiotherapy for rectal cancer using a 2D-DIGE (difference gel electrophoresis) 
quantitative proteomic approach in 35 patients with rectal cancer found higher Prx4 
expression in pre-treatment tumour samples in poor responders to chemoradiotherapy, 
suggesting a potential role as a predictive biomarker of response to chemoradiotherapy for 




3.4.5 Peroxiredoxin 5 
There is limited literature available on the role of Prx5 in CRC, but a recent study 
demonstrated increased expression of Prx5 in colon cancer cell lines is associated with cell 
proliferation, migration and invasion, while decreased expression had the inverse effect 
(230). This study also found enhanced tumour growth with increased expression of Prx5 in a 
xenograft mouse model. There are no reports relating to Prx5 in human CRC. 
3.4.6 Peroxiredoxin 6 
Wu et al demonstrated Prx6 expression positivity in 56% of CRC tissue vs 12.5% of normal 
control tissue, and significantly higher expression in CRC tissue on western blotting, but no 
association with clinical stage or lymph node metastases (219). There are no other reports 
linking Prx6 to CRC development, progression or treatment response.  
3.5 Peroxiredoxins as Prognostic and Predictive Biomarkers 
Tumour biology is often the most important determinant of patient outcome, and tumour 
features can be useful for predicting the natural history of CRC. There is significant evidence 
to support an association between increased Prx2 expression and poor prognostic factors 
such as more advanced tumour stage and decreased survival. Prx1 has also been associated 
with clinical outcomes. Peroxiredoxins may be one marker of the underlying tumour biology 
as redox homeostasis itself is critical to cell survival. 
The studies described above suggest that peroxiredoxin expression level may have a role in 
predicting radiosensitivity and/or chemosensitivity for CRC. The majority of this evidence is 
based on work with cell lines or animal models, with limited evidence of in vivo response to 
treatment in human subjects. Only Prx1 and Prx4 have been linked to radiotherapy response 
for rectal cancer in vivo, and each by a single study. Prx2 has not yet been linked to response 
to radiotherapy for rectal cancer but an apparent role in the development, progression and 
in vitro response to chemo/radiotherapy of CRC makes it a good candidate for further 
investigation. 
Peroxiredoxins are sensitive markers of cellular redox homeostasis. Typical 2-Cys 
peroxiredoxins can be present in oxidized homodimers (~40kD) or reduced monomers 
(~20kD), with the oxidized form accumulating in cells due to either increased rates of 
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hydroperoxide generation or limitations in the rate of reduction of the oxidized forms (193). 
A simple method of measuring the oxidized and reduced forms of peroxiredoxins exists by 
western blotting of samples in which proteins have been separated by non-reducing 
polyacrylamide gel electrophoresis, and the relative ratio of oxidized and reduced 
peroxiredoxin calculated. This methodology has been shown to be valuable in measuring 
oxidative stress in erythrocytes and cardiac tissue (193) and in cultured cells treated with 
cytotoxic agents such as auranofin and phenethyl isothiocyanate (192, 232). In the studies to 
date investigating peroxiredoxins in CRC, total peroxiredoxin expression has been assessed, 
but not the redox status. Indeed, no comprehensive analysis of peroxiredoxin redox status in 
tumour material has been reported.  
3.6 Peroxiredoxins as Therapeutic Targets 
Work on expression silencing in laboratory models suggests peroxiredoxin inhibition as a 
possible therapeutic strategy. Various peroxiredoxin inhibitors have been described (233-
235), including inhibitors of mitochondrial Prx3 (236), but there have been no studies 
specifically addressing this in CRC. Inhibition of peroxiredoxins in CRC could result in either 
increased oxidative stress during IR, and may even have direct anti-tumour activity. Another 
potential therapeutic target is the thioredoxin system, which is important in maintaining 
peroxiredoxins in their reduced form. Thioredoxin reductase inhibitors such as auranofin 
have been shown to result in cell death due to mitochondrial dysfunction and hydrogen 
peroxide accumulation in the context of neurological disorders (237) and have been 
proposed as anti-cancer agents based on upregulation in advanced malignancy and 
impairment of tumour growth in human tumour xenografts in mouse models (238). A 
thioredoxin-1 inhibitor has been shown to inhibit growth and progression of CRC cell lines 
(239), and while there has been no examination of radiosensitivity this would be worthy of 
investigation.  
3.7 Summary and Discussion 
Predicting radiation sensitivity of rectal cancer carries enormous clinical significance, 
particularly in the setting of an evolving organ preservation approach to management. Tools 
to assist in management decisions regarding organ preservation strategies would be of 
75 
 
important clinical value. Mitochondrial function including redox homeostasis is integral in 
the cellular response to IR, and peroxiredoxins are important players in these systems. 
There is evidence of increased expression of all six peroxiredoxins in CRC, albeit with some 
inconsistencies among reported associations for Prx2 and Prx4. These inconsistencies 
indicate a need for further research. Prx1, Prx2 and Prx4 appear the most promising as 
prognostic indicators and/or predictive biomarkers of response to radiotherapy for CRC 
based on the available evidence. Prx3, Prx5 and Prx6 have limited data to support a role as 
markers, but what is available does suggest increased expression in CRC and the role of 
these enzymes in CRC is in need of further investigation. Prx3 is of particular interest as the 
only peroxiredoxin present exclusively in mitochondria, given the central role of 
mitochondria in the response to IR. 
The potential to increase cancer cell death and the chance of pathological complete 
response from radiotherapy for rectal cancer is real. Neoadjuvant radiotherapy is commonly 
given with fluoropyrimidine-based therapy as a radiosensitiser. It is possible modulation of 
the peroxiredoxin/thioredoxin system could improve response to chemoradiotherapy for 
rectal cancer by acting on both radiotherapeutic and chemotherapeutic pathways.  
It is difficult to compare the radiotherapy response for colon and rectal tumours due to the 
different uses of radiotherapy in the two sites, and because the clinical behaviour of colon 
and rectal cancer differs significantly despite histological similarity. The clinical utility of 
radiotherapy is much greater for rectal cancer than colon cancer, therefore further 
investigation of the radiotherapy response associated with peroxiredoxin expression and 
redox status would be best studied in human subjects with rectal cancer if the potential for 




4 Markers of Oxidative Stress as Novel Predictors of the Response 
to Radiotherapy for Rectal Cancer 
4.1 Introduction 
Extensive research has been performed attempting to identify predictive biomarkers of the 
response to radiotherapy for rectal cancer (Chapter 1). Common approaches have included 
genetic sequencing and immunohistochemistry to investigate the presence or absence of a 
specific genetic sequence or quantification of a specific protein. Despite the central role of 
oxidative stress in the cytotoxicity of ionising radiation, there has been little research 
investigating the redox status of tumours as a predictive biomarker. Complex dynamic 
systems can be difficult to investigate due to a large number of variables and incomplete 
understanding of the system of interest, particularly redox homeostasis. In this chapter three 
markers of oxidative stress were chosen for assessment: peroxiredoxin 2 and peroxiredoxin 
3 oxidation, and protein carbonyls. None of these have been previously investigated as 
predictors of response to radiotherapy for rectal cancer.  
The background and rationale for investigation of peroxiredoxins as predictors of radiation 
response for rectal cancer is outlined at length in Chapter 3. In summary, oxidative stress is a 
major mode of tumour cell death in radiotherapy. Peroxiredoxins are a family of thiol-
dependent antioxidants and include six different types in human cells, in which they are 
abundant. Peroxiredoxins reduce reactive oxygen species (ROS) with a particular 
effectiveness for hydrogen peroxide, and are therefore central in maintaining redox 
homeostasis in cells. The catalytic activity of peroxiredoxins is dependent on an active 
cysteine residue that is oxidised to a sulfenic acid (240). Peroxiredoxin oxidation is a 
reversible process and oxidised peroxiredoxins are reduced by thioredoxin or glutaredoxin 
meaning the enzymes are recyclable. Oxidised and reduced forms of peroxiredoxins have 
been used as markers of oxidative stress in biological systems as accumulation of the 
oxidised form occurs with sustained oxidative stress (193). Oxidation of peroxiredoxins 
occurs rapidly when exposed to the atmosphere, therefore peroxiredoxins need to be 
trapped in their redox state prior to cell lysis by use of an alkylating agent such as N-
ethylmaleimide (NEM). The ratio of oxidised dimers (~42kD) to reduced monomers (~21kD) 




Figure 4.1. Action of N-ethylmaleimide in trapping the oxidation state of typical 2-Cys peroxiredoxins 
and visualisation on western blotting (reproduced from reference (193)) 
 
Peroxiredoxin 2 (Prx2) and peroxiredoxin 3 (Prx3) are present in different cellular 
compartments (cytosol and mitochondria respectively) and methods of western blotting for 
cell lysates have been shown to be successful previously as indicators of increased oxidative 
stress in cell culture (241) and isolated rat hearts (242). Although peroxiredoxin 1 has been 
suggested as a possible candidate for further research in previous studies examining 
radiosensitivity of CRC (220), it is from the same cellular compartment as peroxiredoxin 2. 
Because western blotting is very antibody dependent, peroxiredoxin 2 was chosen due to 
proven past performance in the laboratory and lack of evidence to suggest there should be a 
major difference between peroxiredoxin 1 and peroxiredoxin 2. No work has been published 
using human tissue. Mitochondria are important sources and targets of oxidative stress, as 
discussed in Chapter 3. Prx3 is a mitochondrial enzyme, and its activity may be increased by 
either specific upregulation or due to an increase in numbers of mitochondria. The number 
of mitochondria present in a cell is dynamic, with production (mitogenesis) and destruction 
(mitophagy) varying according to biological need. 
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Protein carbonyls are biomarkers of global protein oxidation that are generated by several 
different mechanisms during oxidative stress, including direct oxidation of amino acids, 
cleavage of the protein backbone and lipid peroxidation (243). A protein carbonyl is formed 
when an aldehyde or ketone group is added to a side chain, most commonly on arginine, 
proline, threonine and lysine residues, forming a chemically stable compound (243). By 
introducing a detectable functional group into an oxidised protein, for example by 
derivatisation with dinitrophenyl hydrazine (DNP), protein carbonyls can be measured. 
Carbonyls have been demonstrated to be markers of oxidative stress (244) and have been 
investigated in numerous translational studies, including inflammatory conditions such as 
acute pancreatitis (245) and ulcerative colitis (246), infectious diseases such as leptospirosis 
(247) and colorectal cancer (246). They have not been investigated as a predictor of 
response to radiotherapy for rectal cancer. 
4.2 Hypothesis 
Baseline oxidative stress of tumour cells predicts sensitivity to radiotherapy for rectal cancer.  
4.3 Objectives 
The primary objective was to determine the relationship between markers of oxidative 
stress and the response to chemoradiotherapy for rectal cancer. 
The secondary objectives were to assess differences in markers of oxidative stress between 
normal rectal mucosa and rectal tumour tissue, and to assess changes in markers of 
oxidative stress in rectal tumour and normal rectal epithelium after radiotherapy. 
4.4 Methods 
This prospective observational pilot study was conducted from February 1 2018-January 30 
2019. Patients treated for rectal cancer at Christchurch Hospital were recruited by screening 
colonoscopy lists and the colorectal multi-disciplinary meeting (MDM), and liaison with 
clinicians.  
Inclusion required a confirmed rectal tumour in adult patients (>18 years of age). Patients 
were excluded if repeat sigmoidoscopy was required and posed more than minimal clinical 
risk e.g. frail patient, anticoagulants or other medications requiring cessation. 
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4.4.1 Clinical Protocol 
4.4.1.1 Staging 
Routine staging investigations were performed with magnetic resonance imaging (MRI) of 
the pelvis for loco-regional assessment and computed tomography (CT) of the chest, 
abdomen and pelvis to assess for distant metastases. Additional imaging such as MRI liver or 
PET/CT scan was performed when clinically indicated. Imaging interpretation was reported 
by a consultant radiologist in a synoptic manner based on the American Joint Committee on 
Cancer (AJCC) TNM staging system. Serum carcinoembryonic antigen level (CEA) was 
obtained at diagnosis.  
4.4.1.2 Treatment 
The management of each participant was determined by the clinical team with input from 
the MDM and without consideration to the study. This included recommendations regarding 
radiotherapy, chemotherapy and/or surgery.  
Radiotherapy for rectal cancer is relatively standardised in Christchurch Hospital. Short-
course radiotherapy includes 25 Gray in five fractions with surgery usually performed within 
7-10 days. Long-course radiotherapy includes 45 Gray in 25 fractions of whole pelvis 
radiotherapy with a 5.40 Gray boost to the tumour in a total of 28 fractions, and surgery is 
performed 8-12 weeks later. Concurrent chemotherapy is given with long-course 
radiotherapy (nCRT) if the patient does not have precluding co-morbidity, most commonly in 
the form of oral capecitabine. Organ preservation using a watch-and-wait strategy (i.e. 
deferred surgery with surveillance of a complete clinical response) is not routine, but is 
occasionally considered based on individual patient risk profile. 
Rectal resection was carried out by a qualified colorectal surgeon at Christchurch Hospital 
(Canterbury District Health Board). Total mesorectal excision (TME) is employed routinely for 
LARC and may be open, laparoscopic or a trans-anal/laparoscopic combined technique. 
Surgical options include rectal resection with sphincter preservation with or without 
anastomosis (anterior resection), or en-bloc sphincter-excision by abdominoperineal 
resection. The timing of mesenteric vascular ligation was determined by the operating 




All patients gave written informed consent. Patients were recruited by one of two possible 
pathways. Figure 4.2 demonstrates the timeline of each pathway in relation to the common 
clinical pathway. The pre-diagnostic pathway required a two-stage consent process. Patients 
with high suspicion of rectal cancer (determined by JF) were approached prior to diagnostic 
colonoscopy. General consent was obtained for additional colorectal biopsies for research 
purposes. If rectal cancer was confirmed, the patient was approached with further 
information and an additional consent form completed for full enrolment in the study. The 
post-diagnostic pathway was used for patients with a confirmed diagnosis of rectal cancer. If 
flexible endoscopy was planned for clinical reasons (e.g. to confirm histological diagnosis or 
for operative planning prior to neoadjuvant radiotherapy) biopsies were taken at this time. If 
additional flexible endoscopy was not planned rigid sigmoidoscopy and biopsy was 
performed. 
 




4.4.2.1 Clinicopathological Data Collection and Follow-up 
Clinical, pathological and radiological data was recorded for each participant.  The AJCC TRG 
was recorded for each patient treated with radiotherapy who underwent surgical resection. 
Patients were followed until the day of surgery, or until the first repeat sigmoidoscopy and 
biopsy in the event of a complete clinical response (cCR) for which resection was not 
performed. 
4.4.3 Biopsy and Tissue Processing Protocol 
4.4.3.1 Endoscopic Biopsies 
Biopsies were taken from a peripheral location within the tumour, avoiding ulcerated and 
necrotic areas. Biopsies of normal rectal mucosa were taken at least 5 cm from the tumour. 
Normal mucosa was biopsied first to prevent theoretical chance of seeding cancer cells to 
normal tissue, or from an anatomical location expected to be removed at surgery. JF 
directed the endoscopist to ensure optimum tissue sampling, with the exception of two 
cases when the task was delegated to a suitably-qualified individual. Up to ten biopsies were 
taken from each participant using flexible endoscopic biopsy forceps. Due to the larger size 
of biopsies taken with rigid sigmoidoscopy, approximately six biopsies were necessary to 
obtain a similar amount of tissue as obtained from 10 flexible endoscopic biopsies.  
4.4.3.2 Tissue Collection Protocol  
Both tumour and normal tissue biopsy specimens were placed in 1.6 mL Eppendorf tubes 
with either 1 mL phosphate buffered saline (PBS) or 1 mL PBS with 100 mM NEM 
immediately after the biopsy was taken. The time from biopsy to immersion in buffer was 
less than 30 seconds for pre-treatment biopsies; for resection specimen’s tumour and 
normal rectal mucosa tissue was processed within 20 minutes of extraction of the surgical 
specimen using procedures established for the Cancer Society Tissue Bank (CSTB). JF 
attended the operating theatre to expedite transfer of the surgical specimen to Anatomical 
Pathology when possible. Surgical specimens were examined by the consultant pathologist 
or registrar on duty, and both tumour and normal tissue surplus to diagnostic requirements 
was obtained for the study. The PBS + NEM buffer was warmed to room temperature prior 
to biopsy collection, and maintained at room temperature while the PBS samples were 
maintained below 4oC on wet ice. Additional samples of normal and tumour tissue from pre-
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treatment biopsy were snap frozen in the endoscopy suite using dry ice and stored in the 
CSTB. 
4.4.3.3 Tissue Lysate Preparation – Method A 
1. On arrival at the laboratory the tissue was transferred to new Eppendorf tubes 
containing approximately 250 μL of the same buffer (PBS or PBS + 100 mM NEM) 
per endoscopic biopsy. 
2. Biopsy material was homogenised with a glass hand homogeniser in an 
Eppendorf tube as soon as possible, rinsing the homogeniser with water then PBS 
between samples to prevent cross-contamination. 
3. Samples were incubated at room temperature for 15 minutes after 
homogenisation then lysis buffer added and placed on wet ice. Lysis buffer 
contained 40μL 20% sodium dodecyl sulfate (SDS), 100 μL 10% NP-40 detergent, 
100 μL 10% sodium deoxycholate and 25 μL 50x complete protease inhibitor for 
each 1000 μL of buffer. 
4. Samples were sonicated on ice using three five second bursts with 30 second 
pauses between to prevent samples from overheating.  
5. Centrifuged at 12,000 g for 20 minutes at 4 oC. 
6. Supernatant was collected into a new 1.6 mL Eppendorf tube and frozen, pellet 
discarded. 
7. Samples aliquoted on first thawing after measuring protein content and 
subsequently stored in -80 oC freezer. 
4.4.3.4 Tissue Lysate Preparation – Method B 
Later samples were homogenised using the Precellys Evolution Cryolys bead homogeniser 
(Bertin Instruments) after determining equivalent results with both methods. Steps 1-3 were 
identical to Method A and subsequent steps are below. 
1. Placed in 2 mL reinforced tube with fresh buffer. Ceramic 2.8 mm beads (CK28R) 
used on advice from a Bertin Instruments scientific representative. 
2. Spun for three 15 s cycles with 30 second gap between each, maintained at 4 oC.  
3. Lysis buffer added. 
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4. Centrifuged for five minutes at 4 oC to remove bubbles then transferred to 
Eppendorf and steps 5-7 in Method A followed. 
To compare the two methods of tissue homogenisation, the same biopsy tissue was 
processed by the two methods (Method A and Method B) in parallel. Comparison of ‘9R’ 
resection specimen processed by both methods was found to have similar total protein 
concentration and a western blot demonstrated similar %Prx2ox (not shown). 
4.4.3.5 Protein Quantification 
Protein concentration was measured using the DC™ Protein Assay (Bio-Rad). The DC™ 
Protein Assay is a detergent compatible colorimetric assay for protein concentration 
modified from the Lowry assay. Absorbance was measured in a microplate reader and 
related to a standard curve constructed on each occasion using bovine serum albumin (BSA). 
The microassay method was used in this study due to limited sample volumes available. 
Protein quantification was performed in duplicate or triplicate.  
4.4.3.6 Gel Protein Electrophoresis and Western Blotting 
Tissue lysate was used to perform sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) on a non-reducing gel. Non-reducing gels were used because the ratio of 
oxidised to reduced forms of peroxiredoxins was the main outcome of interest, and a 
reducing gel would prevent assessment of this. Mini-PROTEAN® TGX™ precast gels (Bio-Rad 
Laboratories, Inc) were used.  Protein was transferred from the gel to a polyvinylidene 
difluoride (PVDF) membrane and then immunostaining performed using the western blot 
technique. Membranes were blocked for one hour (using 5% milk or 5% BSA) then the 
primary antibody was applied and incubated overnight at 4 oC (Table 4.1). The following day 
the membranes were washed with at least three washes of at least five minutes each with 
Tris-buffered saline and Tween 20 (TBST) then incubated in the secondary antibody for one 
hour at room temperature. Blots were washed again then developed using the Alliance Q9 












Primary antibody  (concentration) Secondary antibody (concentration) Blocking agent Incubating agent 
Prx2 5μg Anti-peroxiredoxin 2 (C-terminal) rabbit polyclonal 
antibody, R8656, Sigma-Aldrich (1:20,000) 
Goat anti-rabbit secondary antibody 
(Horseradish Peroxidase) (1:10,000) 
5% w/v skim 
milk in TBST 
5% w/v skim milk 
in TBST 
Prx3 25μg Anti-peroxiredoxin 3 rabbit polyclonal antibody, LF-
PA0255, Abfrontier (1:7500) 
Goat anti-rabbit (Horseradish Peroxidase) 
(1:10,000) 
5% w/v BSA in 
TBST 






4.4.3.6.1 Quantification of Western Blots 
Image J software (National Institute of Health and Laboratory for Optical and Computational 
Instrumentation, University of Wisconsin) was used to perform densitometry. Image J was 
used to open the TIF file and the bands of interest were isolated using the rectangle tool. For 
peroxiredoxins the same frame was used to measure oxidised and reduced bands for each 
sample. The band intensity peaks were plotted, the peaks were separated using the line tool, 
and the area under each peak measured.  
For Prx2 and Prx3 the percentage of peroxiredoxin oxidation (%Prxox) was calculated using 
the equation: 
%𝑃𝑟𝑥𝑜𝑥 =  
𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑 𝑝𝑒𝑟𝑜𝑥𝑖𝑟𝑒𝑑𝑜𝑥𝑖𝑛)
𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (𝑜𝑥𝑖𝑑𝑖𝑠𝑒𝑑 𝑝𝑒𝑟𝑜𝑥𝑖𝑟𝑒𝑑𝑜𝑥𝑖𝑛) + 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (𝑟𝑒𝑑𝑢𝑐𝑒𝑑 𝑝𝑒𝑟𝑜𝑥𝑖𝑟𝑒𝑑𝑜𝑥𝑖𝑛)
 × 100 
4.4.3.7 Protein Carbonyl Measurement by Enzyme-Linked Immunosorbent Assay (ELISA) 
Protein carbonyls were measured using materials and methods available in a commercial 
enzyme-linked immunosorbent assay (ELISA) kit (BioCell Protein Carbonyl Assay Kit). This 
ELISA involves derivatisation of protein samples with DNP which are then bound to the ELISA 




Figure 4.3. Outline of the protein carbonyl ELISA (reproduced from reference (248)) 
4.5 Results 
23 patients were recruited during the study period. Diagnoses and treatment received are 
summarised in Table 4.2; three patients were found not to have rectal adenocarcinoma as 
initially suspected. One patient was excluded from analysis as they were diagnosed with 
locally advanced prostate carcinoma invading the lumen of the rectum. Two patients had 
advanced adenomas treated by local excision (ID 13 and ID 21); these patients were included 
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in comparison between tumour tissue and normal tissue but not in analysis related to 
treatment outcomes. For the 22 patients included, the median age was 67 (range 36-85) and 
15 were male. All were of NZ European ethnicity except for one who was of Maori ethnicity. 
Pre-treatment clinicopathological data is reported in Table 4.2, with the sub-group used to 
assess predictors of response presented separately. Patients treated by nCRT and TME, or 
nCRT with a complete clinical response managed with a watch-and-wait strategy, were 
included in analysis to determine predictors of response to CRT (n=7).  
Table 4.2. Treatment strategies employed for participants recruited 
Diagnosis Treatment N (%) 
Rectal 
adenocarcinoma  
nCRT and TME performed 6 
nCRT with deferral of surgery due to complete clinical response 1 
Short-course radiotherapy and TME 3 
Straight to surgery, no neoadjuvant treatment 2 
Palliative treatment (no surgery) 2 
nCRT with TME planned 6 








Table 4.3. Clinicopathological data for participants recruited 
 N all patients (n=22) N (nCRT and TME) 
and cCR (n=7) 



















BMI median (range) 28.2 29.6 (24.7-33.7) 
Diabetes 2 1 
Smoker (within 30 days) 3 0 
























Distance from anorectal margin on MRI (mm), 
median (range) 


















Circumferential or near 


















Tumour length on MRI (mm), median (range) 45 (26-75) 47 (32-66) 
CEA, median (range)* 3.5 (0.7-26.7) 8.65 (1.3-26.7) 
*rectal cancer only 
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Operative and pathological outcomes for patients who underwent TME after nCRT are 
presented in Table 4.4. 
Table 4.4. Operative and pathological outcomes for patients who underwent TME following 
neoadjuvant chemoradiotherapy 




























Mucinous  0 
LVI 0 

























4.5.1 Assessment of Markers of Oxidative Stress 
4.5.1.1 Peroxiredoxin 2 Oxidation 
Western blotting for Prx2 yielded consistently good results with clear blots, minimal 
background and only 5 µg of total protein required (representative blot in Figure 4.4). 
Densitometry performed for duplicates of lysate samples and subsequent %Prx2ox calculated 
is shown in Figure 4.5 and Figure 4.6, demonstrating less than 10% variability for most 
samples.  
 






Figure 4.5. Variability in duplicate measurement 
of peroxiredoxin 2 percentage oxidation of 
normal samples 
 
Figure 4.6. Variability in duplicate measurement 
of peroxiredoxin 2 percentage oxidation of 
tumour samples 
 
4.5.1.2 Peroxiredoxin 3 Oxidation 
In general Prx3 western blots were poorer quality with low signal, high background and the 
presence of a non-specific band at 15 kD despite best attempts at optimisation 
(representative blot in Figure 4.7, although non-specific band is not obvious in this figure). 
Methods of optimisation included increasing total protein to 25 µg, trying multiple different 
primary antibodies (Abcam Ab202120, ABfrontier AF17D2FF), increasing the concentration 
of the primary antibody, using a high-sensitivity chemiluminescent reagent and blocking and 
incubating in BSA instead of milk.  
As shown in Figure 4.8 and Figure 4.9 the reproducibility was generally poorer, especially for 









Figure 4.8. Variability in duplicate measurement 
of peroxiredoxin 3 percentage oxidation of 
normal samples 
 
Figure 4.9. Variability in duplicate measurement 





4.5.1.3 Comparison of Normal Tissue and Tumour Samples 
There was no significant difference overall between mean %Prx2ox in normal (mean 67.6, SD 
2.96) and tumour samples (mean 66.6, SD 5.74) on a student’s t test. There was a trend for 
tumour tissue oxidation to be less than normal tissue oxidation for most samples (Figure 
4.10); 4/21 samples tumour was more oxidised compared with 17/21 normal tissue was 
more oxidised. Sample 16T is seen as an outlier with approximately 90% oxidation in Figure 
4.10; this is likely a result of very low signal on western blotting (see Figure 4.4) therefore 
this sample was excluded from subsequent analysis.  
 
Figure 4.10. Relationship between peroxiredoxin 2 percentage oxidation for normal and tumour 
samples 
 
It was possible to calculate %Prx3ox for 17 normal tissue samples and 15 tumour samples. 
9/17 (52.9%) samples were more oxidised in tumour than in normal tissue (Figure 4.11). 
There was no difference in mean %Prx3ox between normal (mean 68.8, SD 16.0) and tumour 
tissue (mean 72.0, SD 15.1) with a mean of difference 5.442, SEM of differences 3.265 (95% 
CI -1.418 – 12.30, p=0.1129). Standard deviations were larger for %Prx3ox than %Prx2ox 




Figure 4.11. Relationship between peroxiredoxin 3 percentage oxidation for normal and tumour 
samples 
 
Data was available for 22 normal and tumour biopsies (including two advanced adenomas, 
ID13 and ID21) for analysis using the protein carbonyl ELISA. There was no significant 
difference between mean carbonyls in normal tissue (mean 0.33 nmol/mg of protein, SD 
0.21) compared with tumour tissue (0.31 nmol/mg of protein, SD 0.26) with a mean 
difference of 0.01973, SEM of differences 0.05337 (95% CI -0.1307 to 0.09127, p= 0.72). The 
results are shown in Figure 4.12. 
 




4.5.1.4 Comparison of Markers of Oxidative Stress for Responders and Non-responders 
Due to low numbers of patients that underwent both nCRT and TME in the study period, pCR 
(n=2) and cCR (n=1) were combined as complete responders (CR). The outcome was also 
assessed by categorising patients by good response (GR) for TRG 0-1 or no GR for TRG 2-3. 
For the seven patients used to assess predictors the four biomarkers examined are 




Table 4.5. Markers of oxidative stress as predictors of response after nCRT 
Participant 
ID 
%Prx2ox %Prx3ox Carbonyls (nmol/mg 
of protein) 
Normal Tumour Normal Tumour Normal Tumour 
Complete Response 
1 74.0 62.1 78.4 79.4 0.200 0.746 
10 69.4 68.7 64.4 76.5 0.406 0.350 
11 67.5 67.0 NR 61.8 0.420 0.186 
No Complete Response 
2 70.4 62.1 62.9 83.2 0.067 0.020 
7 70.3 67.2 100.0 NR 0.680 0.925 
14 65.4 71.0 74.4  95.8 0.464 0.191 
16 64.6 87.2 54.8 62.6 0.481 0.443 
Good Response (TRG 0-1) 
1 74.0 62.1 78.4 79.4 0.200 0.746 
2 70.4 62.1 62.9 83.2 0.067 0.020 
11 67.5 67.0 NR 61.8 0.420 0.186 
16 64.6 87.2 54.8 62.6 0.481 0.443 
No Good Response (TRG 2-3) 
7 70.3 67.2 100.0 NR 0.680 0.925 
10 69.4 68.7 64.4 76.5 0.406 0.350 
14 65.4 71.0 74.4  95.8 0.464 0.191 




Figure 4.13. Peroxiredoxin 2 percentage oxidation 
in normal and tumour tissue for patients with and 
without complete response 
 
Figure 4.14. Peroxiredoxin 2 percentage 
oxidation in normal and tumour tissue for 
patients with and without good response 
 
%Prx2ox for CR compared with no CR and GR compared with no GR is shown in Figure 4.13 
and Figure 4.14 respectively. There was no significant difference between normal and 
tumour samples when CR/no CR and GR/no GR were considered as outcomes. Participants in 
the CR group had lower %Prx2ox in tumour tissue than normal tissue pre-treatment, 
although for two of the samples the difference was slight and the tumour and normal tissue 





Figure 4.15. Peroxiredoxin 3 percentage 
oxidation in normal and tumour tissue for 
patients with and without complete response 
 
Figure 4.16. Peroxiredoxin 3 percentage 
oxidation in normal and tumour tissue for 
patients with and without good response 
 
There was no significant difference between the %Prx3ox of CR/no CR and GR/no GR (Figure 




Figure 4.17. Protein carbonyl levels in normal 
and tumour tissue for patients with and 
without complete response 
 
Figure 4.18. Protein carbonyl levels in normal and 





There was no significant difference between the CR/no CR and GR/no GR groups for 
carbonyl level (Figure 4.17 and Figure 4.18). There was no trend in relative carbonyls 
between normal and tumour tissue. 
4.5.1.5 Correlation Between Markers of Oxidative Stress 
There was no significant correlation between markers of oxidative stress in tumour samples 
or normal biopsies when considered separately [%Prx2ox and %Prx3ox (normal r=0.1859, 
p=0.43; tumour r=0.06324, p=0.79), carbonyl and %Prx2ox (normal r=-0.1879, p=0.41; 
tumour r=0.1651, p=0.49)]. There was also no correlation when tumour and normal samples 
were combined (see Figure 4.19 and Figure 4.20). Only those participants with a valid result 






Figure 4.19. Peroxiredoxin 2 percentage 
oxidation vs. protein carbonyl level 
 
Figure 4.20. Peroxiredoxin 3 percentage 
oxidation vs. peroxiredoxin 2 percentage 
oxidation 
4.5.1.6 Changes in Peroxiredoxin 2 Percentage Oxidation after Radiotherapy (CRT and SCRT) 
5/7 normal tissue samples and 6/7 tumour tissue samples were found to have less %Prx2ox in 
the resection specimen than in the pre-treatment sample. Mean %Prx2ox was significantly 
lower for resection biopsies than pre-treatment biopsies for normal tissue on paired samples 
t test; the mean difference was 5.95 and SEM of differences 2.244 (95% CI 0.4585 -11.44, 
p=0.038) (Figure 4.21).  There was also significantly less mean %Prx2ox in tumour from 
resection specimens compared with pre-treatment biopsies, mean difference 4.312, SEM of 
differences 1.257 (95% CI 1.081 -7.542, p = 0.0186). The highest %Prx2ox in the ‘Resection 
Tumour’ catgeory (red triangle in Figure 4.21) was a biopsy of mucosal scar in patient who 




Figure 4.21. Variation in peroxiredoxin 2 percentage oxidation between pre-treatment and post-
resection biopsies. Colours represent individial participants 
4.6 Discussion 
This study explored the use of oxidative stress biomarkers to predict the response of rectal 
cancer to radiotherapy. None of the markers that were examined have been investigated 
before in this setting, and there is no published literature assessing peroxiredoxin oxidation 
status in human tissue. This study has shown that this laboratory technique, most commonly 
performed in basic science and cell culture settings, can yield results in translational 
research. There are many more uncontrolled variables in obtaining tissue samples from 
human participants and the chasm between getting results from cell culture and real-life 
patient samples can be large. This study has also shown the potential to measure specific 
features of a complex functional biological system in translational research. Biomarkers that 
are focused on gene or protein presence or absence do not always consider that the activity 
of genes/proteins may not be a direct reflection of presence/quantification etc. i.e. activity is 
not always directly correlated with expression. 
The primary aim of this pilot study was to ascertain whether the three biomarkers selected 
could act as predictive biomarkers of pathological response to radiotherapy for rectal 
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cancer.  None of the markers investigated showed a significant association with pathological 
response. Although numbers were small overall, 2/7 participants achieved pCR which is 
higher than the expected pCR rate of 20% for this small group of participants. There was also 
an additional cCR, which although not identical to pCR, may act as a surrogate when 
participant numbers are low.  This was a fortunate occurrence, because it allowed 
examination of the difference between responders and non-responders without large 
recruitment numbers overall. Only a marked difference is likely to have shown up in a study 
of this size, but a robust predictor needs to have high sensitivity and specificity, and it is 
reasonable to conclude that the markers of oxidative stress examined are unlikely to yield a 
clinically useful biomarker predictor using the methods described in this study. 
Comparing markers of oxidative stress in tumour tissue and normal tissue, there was not a 
significant difference in absolute values for any marker. However when the relative Prx2 
oxidation of tumour was compared with a paired normal sample there was generally less 
oxidation in tumour samples than in normal tissue. Tumours have long been stated to have 
higher levels of oxidative stress than normal tissue due to altered metabolic activity, 
transient hypoxia or infiltrating immune cells, although the evidence for this is relatively 
limited and based on cell culture studies (249). This raises the possibility that either there is 
not increased oxidant generation or there has been a concomitant increase in antioxidant 
defences. If anything Prx3 was more oxidised in tumour tissue, but difficulty with obtaining 
quality Prx3 blots limits interpretation of this.  There was no difference in protein carbonyls 
when comparing normal and tumour tissue. 
When %Prx2ox was compared in pre-treatment and resection specimen samples, there was 
significantly more oxidation in pre-treatment than resection samples for both normal and 
tumour tissue. This was the opposite to expected, both because radiotherapy increases 
oxidative stress and because vascular ligation up to two hours before biopsy for the study 
was taken would also be expected to increase oxidation of peroxiredoxins. It may be that 
true oxidation in resection samples was even lower than what was measured but this is 
speculative. 
The study found no correlation between markers of oxidative stress. This was not necessarily 
unexpected, as the mechanisms determining each marker are different and this is the reason 
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four different markers were chosen. It is difficult to draw any more meaningful conclusions 
from this. 
There are a large number of limitations to this study. Study numbers overall were small, and 
the number of patients who underwent nCRT and TME was much lower due to attrition to 
alternative treatment strategies and treatment courses prolonged beyond the defined study 
period. Other limitations relate to uncontrolled variation in tissue sampling, tissue 
processing, western blotting and densitometry measurement.  
Two advanced adenomas were included in the analysis which can be perceived as a 
weakness, but these results were in line with adenocarcinoma results and they were both 
large polyps with significant invasive potential. The inclusion of adenomas was not 
responsible for any significant finding. 
Tumours are likely to have both intra and inter-tumoural variability in cell types. Oxidative 
stress is dynamic and will be affected by alterations to normal physiology including blood 
flow and inflammation. This could mean sampling the same tumour could yield different 
results based on location of the biopsy or fluctuating degrees of inflammation. Attempts 
were made to account for this by standardising tumour sampling as much as possible, but all 
tumours are unique and complete standardisation is not possible. Even normal tissue 
showed significant variation in the biomarkers examined, and normal tissue is likely to be 
more homogeneous than tumour tissue. Although we took normal tissue 5 cm from the 
tumour, it is possible there is a regional change in oxidative stress affecting both tumour and 
adjacent normal rectum due to an inflammatory response to the tumour. 
Endoscopic biopsies are small, reported in the range of 3-10 mg (250). A small piece of tissue 
is generally more susceptible to oxidation with atmospheric exposure but a smaller piece of 
tissue will be penetrated more easily by NEM which will assist in trapping oxidation status of 
peroxiredoxins. Although predictable at the start of the study, it is impossible to say how this 
could have affected results. 
Comparing density of band across different gels on different days with different conditions 
significantly impacts on reproducibility and comparability. By calculating the ratio of oxidised 
to reduced forms within a gel lane, some of this variability is negated as identical protein 
loading is assured for oxidised and reduced forms of each sample. Many of the densitometry 
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measurements could be reproduced with 10-20% variability which is usually regarded as 
satisfactory for an experimental method, %Prx3ox being an exception to this.  
We have been unable to measure total peroxiredoxin amounts with this method but this 
could be done by comparing with recombinant protein of known quantities. It is possible 
that more oxidation is occurring in some samples because there is less peroxiredoxin overall 
for that sample, so more of it is oxidised. 
Western blotting is a technique that would have difficulties translating to use in clinical 
medicine due to the extensive time required, variability of results and difficulties with 
quantification. If peroxiredoxin oxidation was established as being of clinical utility, specific 
antibodies for the oxidised and reduced forms could be developed and used for 
immunohistochemical analysis in routine histopathological assessment. 
This was a pilot study attempting to demonstrate the ability to assess the biomarkers of 
interest in human samples, and to look for any sign of associations with response in order to 
ascertain whether or not a larger scale study would be of benefit. It was a resource intensive 
study, and required a full-time researcher to identify patients, be constantly available to 
collect samples and process them immediately, quantify protein and manage sample 
storage. For a larger scale study the resources would be increased further and must be 
justified on the likelihood of a useful outcome. At this stage a larger scale replication of this 





5 Summary and Future Directions 
This thesis has examined predictors of pathological response to chemoradiotherapy for 
rectal cancer. This was initially done by systematically reviewing the literature to ascertain 
the currently available evidence. The main findings from this systematic review were that 
clinical T and N stage, tumour size and CEA offer some predictive ability; they are routinely 
available and therefore their use is easily justified. Overall however, currently available 
predictors have very limited utility despite a vast amount of work on the subject. 
Subsequently a retrospective study was described in chapter 2 which identified 
clinicopathological predictors in 164 patients at Christchurch Hospital for the period 2013-
2018. This supported previously reported findings of lower clinical nodal stage and smaller 
tumour size being associated with pCR. It also found BMI and anterior tumour position to be 
independent predictors of minimal-poor response by dichotomised TRG, results not 
previously reported.  An attempt to create a clinical scoring system with genuine utility was 
unsuccessful based on the predictors identified in the study. 
A literature review of the effect of ionising radiation on mitochondria and antioxidant 
systems in rectal cancer, with a specific focus on the peroxiredoxin family of antioxidants, 
formed chapter 3. This chapter outlined the theoretical basis for investigation of markers of 
oxidative stress, specifically peroxiredoxins, and the relevance these enzymes have to rectal 
cancer as potential predictors of radiosensitivity and targets for modulation of 
radiosensitivity.  
Based on the background presented in chapter 3, chapter 4 reported a prospective pilot 
study investigating markers of oxidative stress as novel predictive biomarkers of the 
response to radiotherapy for rectal cancer. Peroxiredoxin oxidation status and protein 
carbonyls have been shown in previous studies to be biomarkers of oxidative stress in 
human cells. Although this study established the viability of laboratory techniques 
quantifying percentage oxidation of peroxiredoxins that has not been reported before in 
translational research, it failed to identify a significant predictor of response. Peroxiredoxin 
2, peroxiredoxin 3 and protein carbonyls were not found to have any predictive ability for 
the pathological response to radiotherapy for rectal cancer. It is a long-held belief that 
tumour cells are under increased oxidative stress, and radiotherapy is known to induce 
massive oxidative stress in cells. It is likely that oxidative stress plays a major role in tumour 
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cell death by radiotherapy, but redox homeostasis is a complex system. A marker of balance 
in one antioxidant system may not be a clinically useful marker because compensatory 
antioxidant systems may be upregulated. Tumour heterogeneity is a significant issue that 
can detract from reproducibility of laboratory techniques such as those used in chapter 4. 
Tissue samples from one area of tumour might vary significantly from elsewhere, and 
absolute consistency of sampling is impossible as all tumours are unique. This is a major 
limitation of the experimental work performed and a challenge to overcome in future work 
in the field. Markers of oxidative stress remain potential predictors of pathological response 
to radiotherapy for rectal cancer, but alternative avenues need to be explored. The role of 
oxidative stress in carcinogenesis is a developing field, and there remains much that is 
unknown about the role of oxidative stress in human colorectal carcinogenesis (251). As the 
exact redox mechanisms leading to colorectal cancer development and progression are 
elucidated in humans, the most promising lines of investigation should become apparent 
with regard to radiosensitivity of rectal cancer. It is however likely that a complete 
understanding of redox homeostasis will not be achieved for some time, and an inability to 
account for a large number of factors in vivo may even prevent this approach being 
introduced to clinical practice. 
This thesis has focused on identification of predictors of response to radiotherapy for rectal 
cancer, but the ability to manipulate tumour biology to promote cancer cell death is the 
logical next step if a modifiable aspect of a biological system was found to influence 
response to therapy. It is possible to induce oxidative stress in laboratory models through 
the addition of reactive oxidants, and the ability to induce oxidative stress in tumour cells in 
vivo could increase radiosensitivity or even provide a mode of tumour cell death as a stand-
alone treatment. This work is currently far from clinical practice but there is significant 
potential for future developments in this area. A strategy to increase radiosensitivity which 
has been explored for cervical and head and neck squamous cell carcinoma is hyperbaric 
oxygen delivery (252). The evidence for efficacy is limited, and logistical difficulties in 
delivering hyperbaric oxygen in close temporal association with radiotherapy limits the use 
of this, as well as the potential for increased side effects from the effect on irradiated normal 
tissue. These limitations could possibly be overcome if techniques to increase oxygen 
tension could be targeted to tumour tissue. 
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The strengths of this thesis are that a global view of predictors of response to radiotherapy 
has been taken, considering clinical, biomarker and radiological predictors. A comprehensive 
review of a large amount of literature provided context and justification for the original 
research in the chapters that followed. Chapter 4 reported a completely novel approach to 
biomarker predictors of the response to radiotherapy for rectal cancer. Specific weaknesses 
have been discussed in each chapter. 
Rectal cancer is a heterogeneous disease. Molecular sub-types of colorectal cancer were 
decided by consensus in 2015 (253) but have yet to be externally validated. It is possible that 
molecular features have some impact on sensitivity to radiotherapy for rectal cancer as they 
are known to impact responsiveness to medical treatment for colorectal cancer (254-257), 
and may provide an avenue for biomarker based prediction in the future. The way forward is 
unlikely to be based on any single category of predictor, but is likely to incorporate the 
strongest predictors from the clinicopathological, biomarker and radiological predictor 
categories to create a composite scoring system. This is difficult to apply and requires large 
patient cohorts both to develop and validate. It is likely to incorporate clinicopathological 
factors already known (e.g. cT and cN stage, tumour size, CEA), and may incorporate novel 
biomarkers and advanced imaging features that have yet to be elucidated.  
Predicting response to treatment is an important aspect of advancing treatment for rectal 
cancer. In a developing era of personalised medicine (258), targeting treatment to a patient 
based on characteristics of their disease is likely to be the way forward. However it is 
achieved, personalising medicine to avoid delivering morbid treatments to large numbers of 
patients while only a modest proportion of people benefit must be a goal for all clinicians, 
especially those treating cancer. In the treatment of rectal cancer the morbidity and 
mortality of surgery and radiotherapy is particularly apparent.  
Rectal cancer has seen major advances in treatment since total mesorectal excision was 
popularised in the 1980s and 1990s and the use of radiotherapy became routine; surgical 
innovation continues with laparoscopic, robotic and transanal total mesorectal excision 
approaches aiming to improve outcomes for our patients. As great as surgical progress is, 
often the best outcome for the patient is achieved when we can avoid the need to operate 
at all. While we must not compromise oncological safety in the pursuit of non-operative 
management, watch-and-wait treatment appears to be a viable alternative that is edging 
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towards mainstream practice (9). The question will be how do we select patients most 
appropriately, and how can we increase the number of patients able to safely receive watch-
and-wait management? Predicting the response to radiotherapy for rectal cancer could be a 






Table A1. Tissue biomarkers investigated in only one study assessed in the systematic review. 
Biomarker Ref  Biomarker Ref 
XRCC1 (95)  CPS1 (259) 
PARP1  (95)  CA-IX (105) 
FGF4 (260)  LDH5 (106) 
FGF2 (46)  PDK1 (106) 
PLK1  (261)  Asparagine 
synthetase  
(262) 
VRK1/ VRK2 (62)  Rsf-1 (263) 
PIGF (104)  Thymidine 
phosphorylase 
(107) 
SDF-1α (104)  ABCC4  (39) 
TCF4  (72)  ANXA1  (264) 





Hsp90 (265)  CD133  (267) 
FAK (268)  SMAC  (269) 
FN1 (270)  NK-KB  (271) 
COL3A1 (270)  GRP78  (272) 
CD34 (64)  Cripto-1  (272) 
CA9 (64)  GOLPH3 (69) 
DNAJC12  (273)  CXCR4 (64) 
REG4  (274)  YKL-40 (275) 
PLA2G2A  (276)  c-Met (275) 
HMGB1 (277)  ERCC1 (116) 
mlh-1 (73)  MTHFR (116) 
msh-2 (73)  DPYD (116) 
Ku70 (73)  CA-IX (105) 
SMAD3 (45)  Beta catenin  (96) 
TGFβ (45)  p27 (101)  
HSD17B2  (278)  HMGCS2  (278) 
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